EMBARGOED FOR EARLY RELEASE: 5:45 A.M. (CT) TUESDAY, JUNE 3, 2014

Media Advisory: To contact Josef Coresh, M.D., Ph.D., call Barbara Benham at 410-614-6029 or email bbenham1@jhu.edu.

Developing therapies for kidney disease can be made faster by adopting a new, more sensitive definition of kidney disease progression, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Renal Association-European Dialysis and Transplant Association Congress.

Chronic kidney disease (CKD) is a worldwide public health problem, with increasing prevalence, poor outcomes, and high treatment cost. Yet, despite the avail­ability of simple laboratory tests to identify people with earlier stages of CKD, there are fewer clinical trials for kidney disease than for other common diseases. One contributing reason may be that the established CKD progression end point (i.e., a doubling of serum creatinine concentration from baseline, corresponding to a 57 percent reduction in estimated glomerular filtration rate [GFR]), is a late event, requiring long follow-up periods and large sample size, which limits the feasibility of kidney-related clinical trials. Improved methods for estimating GFR may allow using smaller decreases in estimated GFR as alternative end points to assess CKD progression, according to background information in the article.

Josef Coresh, M.D., Ph.D., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues with the Chronic Kidney Disease Prognosis Consortium, examined the association of decline in estimated GFR with subsequent progression to end-stage renal disease (ESRD; initiation of dialysis or transplantation). The study included 1.7 million participants with 12,344 ESRD events and 223,944 deaths after repeated measurements of kidney function over a 1 to 3 year baseline period. Data collection took place between 1975 and 2011.

The researchers found that declines in estimated GFR smaller than a doubling of serum creatinine concentration were strongly and consistently associated with subsequent risk of ESRD. A doubling of serum creatinine, corresponding to a 57 percent decline in estimated GFR, was associated with a greater than 30-fold higher risk of ESRD. However, over a 1- to 3-year period, a doubling of serum creatinine concentration was present in less than 1 percent of participants. In contrast, a 30 percent decline in estimated GFR was nearly 10 times more common and was associated with an approximately 5-fold increased risk of ESRD.

“These data provide a basis for understanding the tradeoff between higher risk and lower prevalence in choosing a larger or smaller percentage change in estimated GFR as an outcome when studying CKD progression,” the authors write.

“A doubling of serum creatinine concentration has been accepted by the U.S. Food and Drug Administration as a surrogate end point for CKD progression in clinical trials since 1993. Adoption of a lesser decline in estimated GFR as an alternative end point for CKD progression has the potential to shorten duration of follow-up, reduce costs, and increase efficiency of clinical trials. Consistency of effects over time suggests applicability for shorter as well as for longer trials, which is relevant for diseases that are progressing more rapidly or slowly, respectively.”

(doi:10.1001/jama.2014.6634; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, JUNE 3, 2014

Media Advisory: To contact Yaron Finkelstein, M.D., call Suzanne Gold at 416-813-7654, ext. 202059, or email suzanne.gold@sickkids.ca.

Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a study in the June 4 issue of JAMA.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.

Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of SJS or TEN between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.

Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of SJS or TEN. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.

“In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed recurrence risk in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …” the authors write.

“… these findings are relevant to physicians who care for patients with a history of SJS or TEN. Because most such episodes are drug-induced, the high risk of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions.”

(doi:10.1001/jama.2014.839; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, JUNE 3, 2014

Media Advisory: To contact Eric M. Mortensen, M.D., M.Sc., call Penny Kerby at 214-857-1155 or email Penny.Kerby@va.gov.

In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly increased risk of heart attack, according to a study in the June 4 issue of JAMA.

Pneumonia and influenza together are the eighth leading cause of death and the leading causes of infectious death in the United States. Although clinical practice guidelines recommend combination therapy with macrolides (a class of antibiotics), including azithromycin, as first-line therapy for patients hospitalized with pneumonia, recent research suggests that azithromycin may be associated with increased cardiovascular events, according to background information in the article.

Eric M. Mortensen, M.D., M.Sc., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, and colleagues assessed the association of azithromycin use and outcomes within 90 days of hospital admission, including cardiovascular events (heart failure, heart attack, cardiac arrhythmias) and death, for patients 65 years and older who were hospitalized with pneumonia at any Veterans Administration acute care hospital from fiscal years 2002 through 2012.

The final analysis included 31,863 patients who received azithromycin and 31,863 matched patients who did not, but some other guideline-concordant therapy. The researchers found that 90-day mortality was significantly lower in those who received azithromycin (17.4 percent, vs 22.3 percent). There was also an increased odds of heart attack (5.1 percent vs 4.4 percent), but not any cardiac event (43.0 percent vs 42.7 percent), cardiac arrhythmias (25.8 percent vs 26.0 percent), or heart failure (26.3 percent vs 26.2 percent).

“In this national cohort study of veterans hospitalized with pneumonia, azithromycin use was consistently associated with decreased mortality and a slightly increased odds of myocardial infarction,” the authors write. “To put the balance of benefits and harms in context, based on the propensity-matched analysis, the number needed to treat with azithromycin was 21 to prevent 1 death within 90 days, compared with a number needed to harm of 144 for myocardial infarction. This corresponds to a net benefit of around 7 deaths averted for 1 nonfatal myocardial infarction induced.”

“These findings are consistent with a net benefit associated with azithromycin use in patients hospitalized for pneumonia.”

(doi:10.1001/jama.2014.4304; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, JUNE 3, 2014

Media Advisory: To contact Sana M. Al-Khatib, M.D., M.H.S., call Rachel Harrison at 919-419-5069 or email rachel.harrison@duke.edu.

An examination of the benefit of preventive placement of implantable cardioverter-defibrillators (ICDs) in patients with a less severe level of heart failure, a group not well represented in clinical trials, finds significantly better survival at three years than that of similar patients with no ICD, according to a study in the June 4 issue of JAMA.

Although clinical trials have established the ICD as the best currently available therapy to prevent sudden cardiac death in patients with heart failure, some uncertainties remain regarding preventive use of ICDs in patients seen in clinical practice. Of patients enrolled in randomized clinical trials of prophylactic (preventive) ICDs, the median left ventricular ejection fraction (LVEF; the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat) is well below 30 percent. Because a large number of prophylactic ICDs in the United States are implanted in patients with an LVEF between 30 percent and 35 percent, understanding outcomes associated with the ICDs in such patients is important. The Centers for Medicare & Medicaid Services have designated these patients as an important subgroup for whom more data on ICD effectiveness are needed, according to background information in the article.

Sana M. Al-Khatib, M.D., MH.S., of the Duke University Medical Center, Durham, N.C., and colleagues compared survival in Medicare beneficiaries in the National Cardiovascular Data Registry ICD registry with an LVEF between 30 percent and 35 percent who received an ICD during a heart failure hospitalization with similar patients in the Get With The Guidelines-Heart Failure database with no ICD. The analysis was repeated in patients with an LVEF less than 30 percent.

There were no significant differences in the baseline characteristics of the matched groups (n = 408 for both groups). At 1 year, 24.5 percent of ICD patients died vs 24.9 percent of non-ICD patients. At 3 years, 51.4 percent of the ICD patients died, compared with 55.0 percent of the non-ICD patients, a significantly lower risk of death among patients with an LVEF between 30 percent and 35 percent who received an ICD. Presence of an ICD also was associated with better survival in patients with an LVEF less than 30 percent (3-year mortality rates: 45.0 percent vs 57.6 percent).

The authors write that although the difference in absolute risk by 3 years was not large (3.6 percent), it was significant and close in magnitude to what was observed in other clinical trials of prophylactic ICDs. “These results support guidelines’ recommendations to implant a prophylactic ICD in eligible patients with an LVEF of 35 percent or less.”

(doi:10.1001/jama.2014.5310; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This analysis was funded by a grant from the National Heart, Lung, and Blood Institute. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 27, 2014

Media Advisory: To contact Mark D. Neuman, M.D., M.Sc., email neumanm@mail.med.upenn.edu or call 215-760-7471; or email Jessica Mikulski at Jessica.Mikulski@uphs.upenn.edu or call 215-796-4829. To contact editorial author Paul G. Shekelle, M.D., Ph.D., call Warren Robak at 310-451-6913 or email robak@rand.org.

An analysis of more than 600 class I (procedure/treatment should be performed/administered) American College of Cardiology/American Heart Association guideline recommendations published or revised since 1998 finds that about 80 percent were retained at the time of the next guideline revision, and that recommendations not supported by multiple randomized studies were more likely to be downgraded, reversed, or omitted, according to a study in the May 28 issue of JAMA.

As adherence to recommended clinical practice guidelines increasingly is used to measure performance, guidelines play a major role in policy efforts to improve the quality and cost-effectiveness of care. Past research has established the importance of revising guidelines over time to address advances in research and population-level changes in health risks. Nonetheless, unwarranted variability across guidelines can reduce trust in guideline processes and complicate efforts to promote consistent use of evidence-based practices. Moreover, policies based on recommendations that prematurely endorse practices subsequently found to be ineffective can lead to waste and potential harm. Little is known regarding the degree to which individual guideline recommendations endure or change over time, according to background information in the article.

Mark D. Neuman, M.D., M.Sc., of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and colleagues analyzed variations in class I American College of Cardiology/American Heart Association (ACC/AHA) guidelines (n = 11) published between 1998 and 2007 and revised between 2006 and 2013. The researchers reviewed and recorded all class I recommendations from the first of the 2 most recent versions of each guideline and identified corresponding recommendations in the subsequent version. Recommendations replaced by less determinate or contrary recommendations were classified as having been downgraded or reversed; recommendations for which no corresponding item could be identified were classified as having been omitted.

Out of 619 index recommendations, 495 (80.0 percent) were retained in the subsequent version; 8.9 percent were downgraded, 0.3 percent were reversed, and 10.8 percent were omitted. The percentage of recommendations retained varied across guidelines from 15.4 percent to 94.1 percent.

Among recommendations with available information on level of evidence, 90.5 percent of recommendations supported by multiple randomized studies were retained, vs 81.0 percent of recommendations supported by 1 randomized trial or observational data and 73.7 percent of recommendations supported by opinion. After accounting for guideline-level factors, the odds of a downgrade, reversal, or omission were more than 3 times greater for recommendations based on a single trial, observational data, consensus opinion, or standard of care than for recommendations based on multiple randomized trials.

“… our results may have important implications for health policy and medical practice. The categorization of medical evidence, through guidelines, into stronger and weaker recommendations, influences definitions of good medical practice and informs efforts to measure the quality of care on a large scale. Our findings stress the need for frequent re-evaluation of practices and policies based on guideline recommendations, particularly in cases where such recommendations rely primarily on expert opinion or limited clinical evidence,” the authors write.

“Moreover, our results suggest that the effectiveness of clinical practice guidelines as a mechanism for quality improvement may be aided by systematically identifying and reducing unwarranted variability in recommendations. Finally, our work emphasizes the importance of greater efforts on the part of guideline-producing organizations to communicate the reasons that specific recommendations are downgraded, reversed, or omitted over time.”

(doi:10.1001/jama.2014.4949; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 Editorial: Updating Practice Guidelines

In an accompanying editorial, Paul G. Shekelle, M.D., Ph.D., of the VA West Los Angeles Medical Center, Los Angeles, and RAND Corporation, Santa Monica, discusses the importance of keeping clinical practice guideline recommendations up-to-date.

“The need for surveillance and updating of practice guidelines is increasingly gaining attention. To meet the need, guideline development organizations need to change their focus. This change is not easy. It is not just a matter of resources, although guideline organizations are going to have to devote more resources to active surveillance and maintenance of their guidelines than most probably do at present. It also has to be a change to the mindset, recognizing that keeping existing guidelines up-to-date in a timely way is an important goal for good patient care.”

(doi:10.1001/jama.2014.4950; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 27, 2014

Media Advisory: To contact Peter B. Cotton, M.D., F.R.C.P., F.R.C.S., call Heather Woolwine at 843-792-7669 or email woolwinh@musc.edu.

In certain patients with abdominal pain after gallbladder removal (cholecystectomy), undergoing an endoscopic procedure involving the bile and pancreatic ducts did not result in fewer days with disability due to pain, compared to a placebo treatment, according to a study in the May 28 issue of JAMA.

Post-cholecystectomy pain is a common clinical problem. More than 700,000 patients undergo cholecystectomy each year in the United States, and at least 10 percent are reported to have pain afterwards. Most of these patients have no significant abnormalities on imaging or laboratory testing, and the cause remains uncertain. Many of these patients undergo endoscopic retrograde cholangiopancreatography (ERCP; the use of an endoscope to inspect the pancreatic duct and common bile duct) in the hope of finding small stones or other pathology or in an effort to address suspected sphincter of Oddi (a muscle at the juncture of the bile and pancreatic ducts and the small intestine that controls the flow of digestive juices) dysfunction. Of these patients, some undergo biliary or pancreatic sphincterotomy (surgical incision of a muscle that contracts to close an opening) or both. The value of this endoscopic intervention is unproven and the risks are substantial. Procedure-related pancreatitis rates are 10 percent to 15 percent, and perforations may occur. Many patients have prolonged and expensive hospital stays, and some die, according to background information in the article.

Peter B. Cotton, M.D., F.R.C.P., F.R.C.S., of the Medical University of South Carolina, Charleston, and colleagues randomly assigned patients with pain after cholecystectomy (and with no significant laboratory or imaging abnormalities) to sphincterotomy (n = 141) or sham (placebo; n = 73) therapy, after ERCP. Success of treatment was defined as less than 6 days of disability due to pain in the prior 90 days both at months 9 and 12 after randomization, with no narcotic use and no further sphincter intervention.

The rate of successful outcome at 12 months was 37 percent for the patients assigned to sham procedure, and 23 percent for those assigned to sphincterotomy. The most common reason for failure in both treatment groups (72 percent sphincterotomy, 56 percent sham) was persistent elevation in a pain-disability score, with or without re-intervention or narcotic use.

No clinical subgroups appeared to benefit from sphincterotomy more than others. Pancreatitis occurred in 11 percent of patients after primary sphincterotomies and in 15 percent of patients in the sham group.

Of the nonrandomized patients in an observational study group, 24 percent who underwent biliary sphincterotomy, 31 percent who underwent dual sphincterotomy, and 17 percent who did not undergo sphincterotomy had successful treatment.

“These findings do not support the use of ERCP and sphincterotomy for these patients,” the authors write.

“The finding that endoscopic sphincterotomy is not an effective treatment has major implications for clinical practice because it applies to many thousands of patients.”

(doi:10.1001/jama.2014.5220; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This study was funded by a grant from the National Institutes of Diabetes and Digestive and Kidney Diseases. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 1 P.M. (ET) TUESDAY, MAY 27, 2014

Media Advisory: To contact Marco Pahor, M.D., call Morgan Sherburne at 352-273-6160 or email msherburne@ufl.edu.

Among older adults at risk of disability, participation in a structured moderate-intensity physical activity program, compared with a health education intervention, significantly reduced the risk of major mobility disability (defined in this trial as loss of ability to walk 400 meters, or about a quarter mile), according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American College of Sports Medicine annual meeting.

Mobility—the ability to walk without assistance—is a critical characteristic for functioning independently. Reduced mobility is common in older adults and is an independent risk factor for illness, hospitalization, disability, and death. Limited evidence suggests that physical activity may help prevent mobility disability; however, there are no definitive clinical trials examining whether physical activity prevents or delays mobility disability, according to background information in the article.

Marco Pahor, M.D., of the University of Florida, Gainesville, and colleagues with the Lifestyle Interventions and Independence for Elders (LIFE) study, randomly assigned sedentary men and women (age 70 to 89 years) who were able to walk 400 meters to a structured, moderate-intensity physical activity program (n = 818) conducted in a center and at home that included aerobic, resistance, and flexibility training activities, or to a health education program (n = 817), consisting of workshops on topics relevant to older adults and upper extremity stretching exercises. The adults participated for an average of 2.6 years.  Participants were enrolled at 8 centers across the country.

Major mobility disability (loss of ability to walk 400 meters) was experienced by 246 participants (30.1 percent) in the physical activity group and 290 participants (35.5 percent) in the health education group. Persistent mobility disability (two consecutive major mobility disability assessments or major mobility disability followed by death) was ex­perienced by 14.7 percent of participants in the physical activity group and 19.8 percent of participants in the health education group.

A subgroup with lower physical function at study entry, representing 45 percent of the study population, received considerable benefit from the physical activity intervention.

Serious adverse events were reported by 49.4 percent of participants in the physical activity group and 45.7 percent of participants in the health education group.

“These results suggest the potential for structured physical activity as a feasible and effective intervention to reduce the burden of disability among vulnerable older persons, in spite of functional decline in late life. To our knowledge, the LIFE study is the largest and longest duration randomized trial of physical activity in older persons,” the authors write.

(doi:10.1001/jama.2014.5616; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 1 p.m. ET Tuesday, May 27 at this link.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 20, 2014

Media Advisory: To contact corresponding author T. Scott Stroup, M.D., M.P.H., call Dacia Morris at 646-774-8724 or email morrisd@nyspi.columbia.edu. To contact editorial author Donald C. Goff, M.D., call Lorinda Klein at 212-404-3533 or email Lorindaann.klein@nyumc.org.

 
Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate, found no significant difference on a measure of effectiveness, according to a study in the May 21 issue of JAMA.

Long-acting injectable antipsychotic medications are prescribed to reduce nonadherence to drug therapy and relapse in people diagnosed with a schizophrenia-spectrum disorder. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotic medications has not been previously assessed, according to background information in the article.

Joseph P. McEvoy, M.D., of Georgia Regents University, Augusta and colleagues randomly assigned 311 patients diagnosed with schizophrenia or schizoaffective disorder to receive monthly injections of haloperidol decanoate or paliperidone palmitate for as long as 24 months. The researchers measured rates of efficacy failure, defined as a psychiatric hospitalization, a need for crisis stabilization, a substantial increase in frequency of outpatient visits, a clinician’s decision that oral antipsychotic could not be discontinued within 8 weeks after starting the long-acting injectable antipsychotics, or a clinician’s decision to discontinue the assigned long-acting injectable due to inadequate therapeutic benefit.

The authors found no significant difference in the rate of efficacy failure for patients in the paliperidone palmitate group (49 [33.8 percent]) vs those in the haloperidol decanoate group (47 [32.4 percent]. The most common reasons for efficacy failure were psychiatric hospitalization and clinician discontinuation of study medication due to inadequate therapeutic effect. The researchers note that their findings do not rule out the possibility of a clinically meaningful advantage with paliperidone palmitate.

Regarding adverse effects, on average, participants taking paliperidone palmitate gained weight progressively over time, while those taking haloperidol decanoate lost weight. Treatment with paliperidone palmitate was associated with greater increases in serum prolactin (a hormone), whereas haloperidol decanoate was associated with more akathisia (a movement disorder).

“The results [of this study] are consistent with previous research that has not found large differences in the effectiveness of newer and older antipsychotic medications,” the authors conclude.

(doi:10.1001/jama.2014.4310; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: The study was funded by grants from the National Institute of Mental Health to Drs. McEvoy and Stroup. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 Editorial: Maintenance Treatment With Long-Acting Injectable Antipsychotics Comparing Old With New

“Setting aside the substantial differences in cost between haloperidol decanoate and paliperidone palmitate [approximately $35 vs. $1,000, respectively, per injection], the results from [this] trial suggest that drug selection should be based on anticipated adverse effects rather than efficacy,” writes Donald C. Goff, M.D., of the New York University School of Medicine, and Associate Editor, JAMA, in an accompanying editorial.

“This is true for most antipsychotics, with the notable exception of clozapine, which has established superior efficacy for treatment-resistant schizophrenia but is limited in use due to more serious adverse effects. Although patients may try medications sequentially to identify an optimal agent, this approach may be problematic if adverse effects persist after drug discontinuation, such as weight gain or involuntary movements. Additional data from patient samples exposed for a longer duration to a wider range of antipsychotics are needed to better characterize the relative risk of adverse effects, examine their longer term consequences, and identify biomarkers that will allow a personalized medicine approach. Not only is the compilation of reliable data about these drugs essential, so also is the clear communication of this information to patients as part of the shared decision-making process.”

(doi:10.1001/jama.2014.4311; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 20, 2014

Media Advisory: To contact Mark G. Kris, M.D., call Melissa Morgenweck at 646-227-3633 or email morgenwm@mskcc.org. To contact editorial co-author Boris Pasche, M.D., Ph.D., call Marguerite Beck at 336-716-2415 or email marbeck@wakehealth.edu.

 
Multiplexed testing of lung cancer tumors identified genetic alterations that were helpful in selecting targeted treatments.  Patients that received matched therapy for lung cancer lived longer than patients who did not receive directed therapy, although randomized clinical trials are required to determine if this treatment strategy improves survival, according to a study in the May 21 issue of JAMA.

The introduction of targeted therapy has transformed the care of patients with lung cancers by incorporating tumor genotyping into treatment decisions. Adenocarcinoma, the most common type of lung cancer, is diagnosed in 130,000 patients in the United States and 1 million persons worldwide each year.  Adenocarcinoma is also the type of lung cancer with a higher than 50 percent estimated frequency of actionable oncogenic drivers, which are molecular abnormalities that are critical to cancer development. These drivers are defined as “actionable” because the effects of those abnormalities can be negated by agents directed against each genomic alteration, according to background information in the article.

Mark G. Kris, M.D., of Memorial Sloan Kettering Cancer Center, New York, and colleagues examined the frequency of oncogenic drivers in patients with lung adenocarcinomas, and the proportion of patients in whom this data was used to select treatments targeting the identified driver(s) along with overall survival. From 2009 through 2012, 14 sites of the Lung Cancer Mutation Consortium enrolled patients with metastatic lung adenocarcinomas and tested the tumors of patients who met certain criteria for 10 oncogenic drivers.

During the study period, tumors from 1,007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64 percent). Results were used to select a targeted therapy or clinical trial in 275 of 1,007 patients (28 percent).

The 260 patients with an oncogenic driver and treatment with a targeted agent had a median (midpoint) survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years; and the 360 patients with no driver identified, 2.1 years.

The authors conclude that multiplexed tested aided physicians in selecting lung cancer therapies.  Although individuals with drivers receiving a matched targeted agent lived longer, the study design was not appropriate to reach definitive conclusions about survival differences being attributable to the use of oncogenic drivers.

(doi:10.1001/jama.2014.3741; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This study was entirely supported by a grant from the National Institutes of Health, National Cancer Institute. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, May 20 at this link.

 Editorial: Non-Small Cell Lung Cancer and Precision Medicine

Boris Pasche, M.D., Ph.D., of Wake Forest University, Winston-Salem, N.C., and Stefan C. Grant, M.D., J.D., M.B.A., of the University of Alabama at Birmingham, comment on the findings of this study in an accompanying editorial.

“In summary, the study by Kris et al demonstrates the proof of principle that multiplex testing of actionable driver mutations is feasible and can allow for effective treatment stratification. After decades of small, albeit significant, improvements in the care of patients with lung cancer, the advent of genetic testing of tumors, identification of driver mutations, and development of drugs able to specifically target these mutations, have produced substantial improvements in survival for patients with targetable driver mutations. Although much remains to be done, the incorporation of genomic medicine into the study and treatment of lung cancer represents, at the very least, the end of the beginning for the care of these and other patients with cancer.”

(doi:10.1001/jama.2014.3742; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 20, 2014

Media Advisory: To contact Kim L. Bennell, Ph.D., email k.bennell@unimelb.edu.au.

 
Among adults with painful hip osteoarthritis, physical therapy did not result in greater improvement in pain or function compared with a placebo treatment, but was associated with relatively frequent but mild adverse effects, raising questions about its value for these patients, according to a study in the May 21 issue of JAMA.

Hip osteoarthritis is a prevalent and costly chronic musculoskeletal condition. Clinical guidelines recommend physical therapy as treatment, however costs are significant, and evidence about its effectiveness is inconclusive, according to background information in the article.

Kim L. Bennell, Ph.D., of the University of Melbourne, Australia, and colleagues randomly assigned patients with hip osteoarthritis to attend 10 sessions of either active treatment (n = 49; included education and advice, manual therapy, home exercise, and walking aid if appropriate) or sham treatment (n = 53; included inactive ultrasound and inert gel). For 24 weeks after treatment, the active group continued unsupervised home exercise while the sham group self-applied gel three times weekly.

The researchers found that at weeks 13 and 36 the active treatment did not confer additional benefits over the sham treatment on measures of pain and physical function, which were improved in both groups. The treatment group reported a significantly greater number of adverse events, although these were relatively mild in nature.

“These results question the benefits of such a physical therapy program for this patient population,” the authors conclude.

(doi:10.1001/jama.2014.4591; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

There will also be an audio author interview available for this study at 3 p.m. CT Tuesday, May 20, at JAMA.com.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 20, 2014

Media Advisory: To contact Jeffrey A. Linder, M.D., M.P.H., call Jessica Maki at 617-525-6373 or email jmaki3@partners.org.

Despite clear evidence of ineffectiveness, guidelines and more than 15 years of educational efforts stating that the antibiotic prescribing rate for acute bronchitis should be zero, the rate was about 70 percent from 1996-2010 and increased during this time period, according to a study in the May 21 issue of JAMA.

Acute bronchitis is a cough-predominant respiratory illness of less than 3 weeks’ duration. For more than 40 years, trials have shown that antibiotics are not effective for this condition. Despite this, between 1980 and 1999, the rate of antibiotic prescribing for acute bronchitis was between 60 percent and 80 percent in the United States. During the past 15 years, the Centers for Disease Control and Prevention has led efforts to decrease prescribing of antibiotics for acute bronchitis. Since 2005, a Healthcare Effectiveness Data and Information Set (HEDIS) measure has stated that the antibiotic prescribing rate for acute bronchitis should be zero, according to background information in the article.

Michael L. Barnett, M.D., and Jeffrey A. Linder, M.D., M.P.H., of Brigham and Women’s Hospital, Boston, evaluated the change in antibiotic prescribing rates for acute bronchitis in the United States between 1996 and 2010. For the study, the researchers used data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, which are annual, nationally representative surveys that collect information about physicians, outpatient practices, and emergency departments (EDs), as well as patient-level data including demographics, reasons for visits, diagnoses, and medications.

The researchers found that of 3,153 sampled acute bronchitis visits between 1996 and 2010 that met study inclusion criteria, the overall antibiotic prescription rate was 71 percent and increased during this time period. There was a significant increase in antibiotic prescribing in EDs. Physicians prescribed extended macrolides (a type of antibiotics) at 36 percent of acute bronchitis visits, and extended macrolide prescribing increased from 25 percent of visits in 1996-1998 to 41 percent in 2008-2010. Other antibiotics were prescribed at 35 percent of visits.

“Avoidance of antibiotic overuse for acute bronchitis should be a cornerstone of quality health care. Antibiotic overuse for acute bronchitis is straightforward to measure. Physicians, health systems, payers, and patients should collaborate to create more accountability and decrease antibiotic overuse,” the authors conclude.

(doi:10.1001/jama.2013.286141; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 4 P.M. (CT) MONDAY, MAY 19, 2014

Media Advisory: To contact Rupert M. Pearse, M.D., email r.pearse@qmul.ac.uk. To contact editorial author Elliott Bennett-Guerrero, M.D., call Sarah Avery at 919-660-1306 or email sarah.avery@duke.edu.

 
In a study that included high-risk patients undergoing major gastrointestinal surgery, the use of a cardiac-output guided intervention to improve hemodynamics (blood flow and blood pressure) during and after surgery did not reduce complications and the risk of death after 30 days, compared with usual care. However, when the current results were included in an updated meta-analysis, the intervention was associated with a clinically important reduction in complication rates, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society International Conference.

Estimates suggest that more than 230 million patients undergo surgery worldwide each year, with reported mortality rates between 1 percent and 4 percent. Complications and deaths are most frequent among high-risk patients, those who are older or have other illnesses, and those who undergo major gastrointestinal or vascular surgery, according to background information in the article.

Intravenous fluid and inotropic drugs (medications that affect the force with which the heart muscle contracts) have an important effect on patient outcomes, in particular following major gastrointestinal surgery. Yet they are commonly prescribed using subjective criteria, leading to wide variation in clinical practice. One possible solution is the use of cardiac output monitoring to guide administration of intravenous fluid and inotropic drugs as part of a hemodynamic (blood flow) therapy algorithm (a step-by-step protocol for management of a health care issue). Use of hemodynamic therapy algorithms has been recommended in a report commissioned by the U.S. Centers for Medicare & Medicaid Services and by the UK National Institute for Health and Care Excellence. A recent review, however, has suggested that the treatment benefit may be more marginal than previously believed.

Rupert M. Pearse, M.D., of Queen Mary University of London, and colleagues randomly assigned patients (50 years of age or older) undergoing major gastrointestinal surgery to a cardiac output-guided hemodynamic therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours following surgery (n = 368) or to usual care (n = 366).

The primary outcome, a composite of postoperative complications and death at 30 days following surgery, was met by 36.6 percent of patients in the intervention group and by 43.4 percent in the usual care group. Following adjustment for baseline patient risk factors, the observed treatment effect was not statistically significant. Five patients in the intervention group (1.4 percent) experienced serious adverse cardiac events within 24 hours of the end of the intervention period compared with none in the usual care group.

There were no significant differences for any of the secondary outcomes: pre-defined illness on day 7; infectious complications, critical care-free days, and all-cause mortality at 30 days following surgery; all-cause mortality at 180 days; and length of hospital stay.

The addition of the results of this study with other recent trials in a systematic review found that complications were less frequent among patients treated according to a hemodynamic therapy algorithm (intervention, 488/1,548 [31.5 percent] vs control, 614/1,476 [41.6 percent]. The findings of the effect on mortality indicated borderline evidence, but remained consistent with benefit.

“To the best of our knowledge, this is the largest trial of a perioperative, cardiac output-guided hemodynamic therapy algorithm to date. [This study] was designed to address several limitations in the previous trials,” the authors write.

(doi:10.1001/jama.2014.5305; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 Editorial: Hemodynamic Goal-Directed Therapy in High-Risk Surgical Patients

In an accompanying editorial, Elliott Bennett-Guerrero, M.D., of the Duke Clinical Research Institute, Durham, N.C., comments on the results of the systematic review performed by the authors of this study.

“These results further strengthen the overall conclusion that goal-directed therapy (GDT) of some type is probably beneficial for high-risk patients and has few documented adverse effects. Compared with the previous review, this updated analysis added 7 additional trials and reported statistically significant reductions in complications, infections, and hospital stay for patients who received GDT. These findings are consistent with reports by the Centers for Medicare & Medicaid Services and the National Institute for Health and Care Excellence, which recommend the use of hemodynamic therapy algorithms.”

“The extent to which GDT will be translated into routine practice is difficult to predict and will depend on many factors. Goal-directed therapy is best achieved in environments that emphasize a multidisciplinary team approach to patient care, including anesthesiologists, surgeons, intensivists, and nurses. This approach is exemplified in the perioperative surgical home, which is gaining momentum as a model to improve outcome and reduce costs.”

(doi:10.1001/jama.2014.5306; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

# # #

EMBARGOED FOR EARLY RELEASE: 4 P.M. (CT) SUNDAY, MAY 18, 2014

Media Advisory: To contact Vincent Liu, M.D., M.S., call Ann Wallace at 510-891-3653 or email ann.m.wallace@kp.org.

An analysis that included approximately 7 million hospitalizations finds that sepsis contributed to 1 in every 2 to 3 deaths, and most of these patients had sepsis at admission, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society International Conference.

Sepsis, the inflammatory response to infection, affects millions of patients worldwide. However, its effect on overall hospital mortality has not been fully measured, according to background information in the article.

Vincent Liu, M.D., M.S., of the Kaiser Permanente Division of Research, Oakland, and colleagues quantified the contribution of sepsis to mortality in 2 inpatient groups from Kaiser Permanente Northern California (KPNC) and the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (NIS). The KPNC cohort included 482,828 adults with overnight, nonobstetrical hospitalizations at 21 KPNC hospitals between 2010 and 2012. The NIS, a nationally representative sample of 1,051 hospitals, included 6.5 million adult hospitalizations in 2010. Two approaches were used to identify patients with sepsis: explicit (those with certain sepsis-related codes); and implicit (patients with evidence of both infection and acute organ failure).

Of 14,206 KPNC inpatient deaths, 36.9 percent (explicit) to 55.9 percent (implicit) occurred among patients with sepsis, which was nearly all present on admission. Of 143,312 NIS deaths, 34.7 percent (explicit) to 52.0 percent (implicit) occurred among patients with sepsis. In a 2012 KPNC subset, patients with sepsis meeting criteria for early goal-directed therapy (n = 2,536) comprised 32.6 percent of sepsis deaths.

“Given the prominent role it plays in hospital mortality, improved treatment of sepsis could offer meaningful improvements in population mortality,” the authors write.

The researchers note that patients with initially less severe sepsis made up the majority of sepsis deaths. “Performance improvement efforts in the treatment of sepsis have primarily focused on standardizing care for the most severely ill patients, whereas interventions for treating other patients with sepsis are less well defined. Given their prevalence, improving standardized care for patients with less severe sepsis could drive future reductions in hospital mortality.”

(doi:10.1001/jama.2014.5804; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This work was supported by the Permanente Medical Group, the Kaiser Foundation Hospitals and Health Plan, the Gordon and Betty Moore Foundation, and a grant from the U.S. Department of Veterans Affairs Health Services Research & Development. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

# # #

EMBARGOED FOR EARLY RELEASE: 4 P.M. (CT) SUNDAY, MAY 18, 2014

Media Advisory: To contact Cindy T. McEvoy, M.D., M.C.R., call Tamara Hargens-Bradley at 503-494-8231 or email hargenst@ohsu.edu. To contact editorial author Graham L. Hall, Ph.D., email graham.hall@telethonkids.org.au.

Supplemental vitamin C taken by pregnant smokers improved measures of lung function for newborns and decreased the incidence of wheezing for infants through 1 year, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society International Conference.

More than 50 percent of smokers who become pregnant continue to smoke, corresponding to 12 percent of all pregnancies. Smoking during pregnancy adversely affects lung development, with lifelong decreases in pulmonary (lung) function. At birth, newborn infants born to smokers show decreased pulmonary function test (PFT) results, with respiratory changes leading to increased hospitalization for respiratory infections, and increased incidence of childhood asthma, according to background information on the article. In a study involving primates, vitamin C blocked some of the in-utero effects of nicotine on lung development and pulmonary function in offspring.

Cindy T. McEvoy, M.D., M.C.R., of Oregon Health & Science University, Portland, and colleagues randomly assigned pregnant smokers to receive vitamin C (500 mg/d) (n = 89) or placebo (n = 90). One hundred fifty-nine newborns of pregnant smokers (76 vitamin C treated and 83 placebo treated) and 76 newborns (reference group) of pregnant nonsmokers were studied with newborn PFTs (performed within 72 hours of age)

The researchers found that newborns of women randomized to vitamin C, compared with those randomized to placebo, had improved measures of pulmonary function. Offspring of women randomized to vitamin C had significantly decreased wheezing through age 1 year (15/70 [21 percent] vs 31/77 [40 percent]. There were no significant differences in the 1-year PFT results between the vitamin C and placebo groups.

“Although smoking cessation is the foremost goal, most pregnant smokers continue to smoke, supporting the need for a pharmacologic intervention,” the authors write. Other studies have demonstrated that reduced pulmonary function in offspring of smokers continues into childhood and up to age 21 years. “This emphasizes the important opportunity of in-utero intervention. Individuals who begin life with decreased PFT measures may be at increased risk for chronic obstructive pulmonary disease.”

“Vitamin C supplementation in pregnant smokers may be an inexpensive and simple approach (with continued smoking cessation counseling) to decrease some of the effects of smoking in pregnancy on newborn pulmonary function and ultimately infant respiratory morbidities, but further study is required,” the researchers conclude.

(doi:10.1001/jama.2014.5217; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 Editorial: Smoking During Pregnancy, Vitamin C Supplementation, and Infant Respiratory Health

“The findings from the study by McEvoy et al offer an approach for potentially minimizing the harmful effects of maternal smoking during pregnancy on the respiratory health of infants,” writes Graham L. Hall, Ph.D., of the University of Western Australia, West Perth, Australia, in an accompanying editorial.

“However, achieving smoking cessation should be the primary goal for women who smoke and who intend to or become pregnant. By preventing her developing fetus and newborn infant from becoming exposed to tobacco smoke, a pregnant woman can do more for the respiratory health and overall health of her child than any amount of vitamin C may be able to accomplish.”

(doi:10.1001/jama.2014.5218; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

# # #

EMBARGOED FOR EARLY RELEASE: 4 P.M. (CT) SUNDAY, MAY 18, 2014

Media Advisory: To contact corresponding author Tonya S. King, Ph.D., call Matthew Solovey at 717-531-0003, ext. 287127, or email msolovey@hmc.psu.edu.

In adults with persistent asthma and low vitamin D levels, treatment with vitamin D₃ did not reduce the rate of treatment failure or exacerbation of symptoms, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society International Conference.

In children and adults with asthma, lower vitamin D levels have been linked to impaired lung function, increased frequency of exacerbations, and reduced responsiveness to steroid therapy. Data suggesting that vitamin D supplementation could modify steroid response and reduce airway inflammation have led to questions about whether treatment with vitamin D might improve outcomes in patients with asthma, according to background information in the article.

Mario Castro, M.D., M.P.H., of the Washington University School of Medicine, St. Louis, and colleagues randomly assigned adults with asthma and low vitamin D levels to vitamin D₃ (100,000 IU once, then 4,000 IU/daily for 28 weeks; n = 201) or placebo (n = 207), which was added to treatment with the inhaled corticosteroid ciclesonide.

The researchers found that the addition of vitamin D₃ to ciclesonide did not significantly reduce the rate of first treatment failure (a composite outcome of decline in lung function and increases in use of beta-agonists, systemic steroids, and health care utilization) compared with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1 treatment failure during 28 weeks. Participants most commonly experienced treatment failure due to the need for increased inhaled or systemic steroids (58 percent) or by experiencing an exacerbation of asthma symptoms (46 percent).

There was also no significant reduction in other measured outcomes related to asthma control, airway function, quality of life, or airway inflammation.

“These findings do not support a strategy of therapeutic vitamin D₃ supplementation in patients with symptomatic asthma,” the authors conclude.

(doi:10.1001/jama.2014.5052; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This study was conducted with the support of grants that were awarded by the National Heart, Lung, and Blood Institute. Ciclesonide and levalbuterol were provided without cost by Sunovion Pharmaceuticals Inc. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 4 p.m. CT Sunday, May 18 at this link.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 13, 2014

Media Advisory: To contact corresponding author Mark N. Levine, M.D., call Veronica McGuire at 905-525-9140, ext. 22169; or email vmcguir@mcmaster.ca.

Among patients with a certain type of colorectal cancer with limited spread to the liver, imaging using positron emission tomography and computed tomography (CT) before surgery did not significantly change the surgical treatment of the cancer, compared with CT alone, according to a study in the May 14 issue of JAMA.

Colorectal cancer is a leading cause of cancer death. Approximately 50 percent of patients present with or subsequently develop cancer that has spread (metastases) to the liver. Some patients with liver metastases are candidates for surgery to have the cancer removed. However, unidentified occult (hidden) metastases at the time of surgery can render the operation noncurative. Thus, long-term survival following surgical resection (removal) for colorectal cancer liver metastases is only about 50 percent. Positron emission tomography combined with computed tomography (PET-CT) could help avoid noncurative surgery by identifying patients with occult metastases, according to background information in the article.

Carol-Anne Moulton, M.B., B.S., of the University Health Network, Toronto, Canada, and colleagues randomly assigned patients with colorectal cancer treated by surgery with resectable (surgically removable) metastases based on CT scans to PET-CT (n = 270) or CT only (n = 134) to determine the effect on the surgical management of these patients. The study, conducted between 2005 and 2013, involved 21 surgeons at 9 hospitals in Ontario.

Of the 263 patients who received PET-CT scans, 111 provided new information: 62 were classified as negative and 49 had abnormal or suspicious lesions. Change in management (canceled, more extensive liver surgery, or surgery performed on additional organs) as a result of the PET-CT findings occurred in 8.7 percent of cases; 2.7 percent avoided noncurative liver surgery. Overall, liver resection was performed on 91 percent of patients in the PET-CT group and 92 percent of the control group.

The median (midpoint) follow-up was three years. The researchers found no significant difference in survival or disease-free survival between patients in the PET-CT group vs the control group.

“Many countries struggle to maintain quality health care within existing budgets. This is difficult because of increasing health care costs as a result of an aging population and the expense of new therapies and technologies, including diagnostic and functional imaging,” the authors write.

“Among patients with potentially resectable hepatic metastases of colorectal adenocarcinoma, the use of PET-CT compared with CT alone did not result in frequent change in surgical management.  These findings raise questions about the value of PET-CT scans in this setting.”

(doi:10.1001/jama.2014.3740; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 13, 2014

Media Advisory: To contact Jennifer R. Marin, M.D., M.Sc., call Anita Srikameswaran at 412-578-9193 or email srikamav@upmc.edu.

Between 2006 and 2010, there was a nearly 30 percent increase in the rate of visits to an emergency department for traumatic brain injury, which may be attributable to a number of factors, including increased awareness and diagnoses, according to a study in the May 14 issue of JAMA.

In the last decade, traumatic brain injury (TBI) garnered increased attention, including public campaigns and legislation to increase awareness and prevent head injuries. The Centers for Disease Control and Prevention describes TBI as a serious public health concern, according to background information in the article.

Jennifer R. Marin, M.D., M.Sc., of the University of Pittsburgh School of Medicine, and colleagues used data from the Nationwide Emergency Department Sample (NEDS) database to determine national trends in emergency department (ED) visits for TBI from 2006 through 2010. NEDS is a nationally representative data source including 25 million to 50 million visits from more than 950 hospitals each year, representing a 20 percent stratified sample of EDs.

The researchers found that in 2010 there were an estimated 2.5 million ED visits for TBI, representing a 29 percent increase in the rate of visits for TBI during the study period. By comparison, total ED visits increased by 3.6 percent. The majority of the increase in the incidence of TBI occurred in visits coded as concussion or unspecified head injury. Children younger than 3 years and adults older than 60 years had the largest increase in TBI rates. The majority of visits were for minor injuries and most patients were discharged from the ED.

The authors write that the increase in TBI among the very young and very old may indicate these age groups do not benefit as much from public health interventions, such as concussion and helmet laws and safer sports’ practices.

(doi:10.1001/jama.2014.3979; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Support for this study was provided by the National Heart, Lung, and Blood Institute. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 13, 2014

Media Advisory: To contact Daniel E. Jonas, M.D., M.P.H., call Thania Benios at 919-962-8596 or email thania_benios@unc.edu. To contact editorial co-author Katharine A. Bradley, M.D., M.P.H., call Rebecca Hughes at 206-287-2055 or email hughes.r@ghc.org.

An analysis of more than 120 studies that examined the effectiveness of medications to treat alcohol use disorders reports that acamprosate and oral naltrexone show the strongest evidence for decreasing alcohol consumption, according to a study in the May 14 issue of JAMA.

Alcohol use disorders (AUDs) are common, cause substantial illness, and result in 3-fold increased rates of early death. Treating AUDs is difficult, but may be aided by medications, although only a small percentage (<10 percent) of patients with AUDs receive medications to assist in reducing alcohol consumption, according to background information in the article.

Daniel E. Jonas, M.D., M.P.H., of the University of North Carolina at Chapel Hill, and colleagues conducted a review and meta-analysis to evaluate the benefits and harms of medications for the treatment of adults with AUDs. A search of the medical literature identified 122 randomized clinical trials (RCTs) and 1 cohort study (totaling 22,803 participants) that met criteria for inclusion in the analysis.

Most studies assessed acamprosate (27; n = 7,519), naltrexone (53; n = 9,140), or both. The authors present their results in terms of number needed to treat (NNT), which is the average number of patients who need to be treated to see benefit in one patient.  The NNT to prevent return to any drinking for acamprosate was 12 and was 20 for oral naltrexone (50 mg/d). The NNT to prevent return to heavy drinking was 12 for oral naltrexone (50 mg/d). Head-to-head trials have not established superiority of either medication.

For injectable naltrexone, the authors did not find an association with return to any drinking or heavy drinking but found an association with reduction in heavy drinking days.

Because of its long-standing availability (from the 1950s), clinicians may be more familiar with disulfiram than naltrexone or acamprosate. However, evidence from well-controlled trials of disulfiram does not adequately support an association with preventing return to any drinking or improvement in other alcohol consumption outcomes.

Among medications used off-label (prescribing a drug approved to treat a different condition), moderate evidence supports an association with improvement in some consumption outcomes for nalmefene and topiramate.

“When clinicians decide to use one of the medications, a number of factors may help with choosing which medication to prescribe, including the medication’s efficacy, administration frequency, cost, adverse events, and availability,” the authors conclude.

(doi:10.1001/jama.2014.3628; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This project was funded by the Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Editorial: Bringing Patient-Centered Care to Patients With Alcohol Use Disorders

Katharine A. Bradley, M.D., M.P.H., of the Group Health Research Institute, Seattle, and Daniel R. Kivlahan, Ph.D., of the Veterans Health Administration, Washington, D.C., comment on the findings of this study in an accompanying editorial.

“Treatment of AUD is considered an essential health benefit under health care reform. More patients with AUDs will have insurance, which could increase their access to evidence-based treatments for AUDs. The article by Jonas and colleagues should encourage patients and their clinicians to engage in shared decision making about AUD treatment options. By identifying 4 effective medications for AUD [naltrexone, acamprosate, topiramate, and nalmefene], the authors highlight treatment options for a common medical condition for which patient-centered care is not currently the norm. Patients with AUDs should be offered options, including medications, evidence-based behavioral treatments, and mutual support for recovery. Moreover, patients should expect shared decision making about the best options for them.”

(doi:10.1001/jama.2014.3629; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This work was supported in part by the National Institute on Alcohol Abuse and Alcoholism and the Department of Veterans Affairs. Please see the article for additional information, including financial disclosures, etc.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, MAY 13, 2014

Media Advisory: To contact corresponding author Patrick S.F. Bellgowan, Ph.D., call Hannah Jackson at 918-430-3011 or email hjackson@stfpr.com.
Preliminary research finds that within a group of collegiate football players, those who experienced a concussion or had been playing for more years had smaller hippocampal volume (an area of the brain important for memory) than those with fewer years of football experience, according to a study in the May 14 issue of JAMA. In addition, more years of playing football was correlated with slower reaction time.

The hippocampus is a brain region involved in regulating multiple cognitive and emotional processes affected by concussion and is particularly sensitive to moderate and severe traumatic brain injury (TBI). Emerging evidence suggests that the hippocampus is also vulnerable to mild TBI, as indicated by volume reduction and postconcussion abnormalities of hippocampal function. There are limited data on the long-term anatomical and cognitive consequences of concussion and subconcussive impacts on young athletes, according to background information in the article.

Rashmi Singh, Ph.D., of the Laureate Institute for Brain Research, Tulsa, and colleagues investigated the relationship between years of football playing experience and history of concussion with cognitive performance and hippocampal volume in collegiate football players. The study included 25 players with a history of clinician-diagnosed concussion, collegiate football players without a history of concussion (n = 25), and non-football-playing, healthy controls (n = 25). High-resolution anatomical magnetic resonance imaging was used to quantify brain volumes. Scores on a computerized concussion-related cognitive test were used to assess the athletes.

The researchers found smaller hippocampal volumes in collegiate football athletes compared with healthy control participants. Players with a history of concussion had smaller hippocampal volumes than players without concussion. Number of years of football-playing experience was inversely associated with both hippocampal volume and reaction time.

“The present study design limits our ability to dissociate [regard as unconnected] among the many possible factors involved in these hippocampal volume findings, but our study should serve as an impetus for future longitudinal research to investigate the neuroanatomical and cognitive changes in young contact-sport athletes. The clinical significance of the observed hippocampal size differences is unknown at this time,” the authors conclude.

(doi:10.1001/jama.2014.3313; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by the William K. Warren Foundation. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

# # #

Media Advisory: To contact Jennifer G. Robinson, M.D., M.P.H., call Jennifer Brown at 319-356-7124 or email jennifer-l-brown@uiowa.edu.
Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition of the human monoclonal antibody evolocumab resulted in additional lowering of low-density lipoprotein cholesterol (LDL-C) levels, according to a study in the May 14 issue of JAMA.

Many patients receiving moderate- or high-intensity statin therapy are unable to achieve recommended LDL-C goals, and consideration of non-statin therapy for additional LDL-C lowering has been recommended. In phase 2 studies, evolocumab use was associated with reduced LDL-C levels in patients receiving statin therapy, according to background information in the article.

Jennifer G. Robinson, M.D., M.P.H., of the University of Iowa, Iowa City, and colleagues conducted a phase 3 study (LAPLACE-2) in which patients were assigned to 1 of 24 treatment groups in two steps.  Initially, patients (n = 2,067) were randomly assigned to a daily, moderate-intensity statin (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]); or high-intensity statin (atorvastatin [80 mg], rosuvastatin [40 mg]). After four weeks, while continuing their statin therapy, patients (n = 1,899) were then randomly assigned to compare the effect of evolocumab (140 mg every 2 weeks or 420 mg monthly) with placebo (every 2 weeks or monthly) or ezetimibe (10 mg or placebo daily, atorvastatin patients only; a nonstatin drug used to treat high cholesterol). The study was conducted at 198 sites in 17 countries.

Compared with placebo, evolocumab provided clinically equivalent percent reductions in LDL-C levels when administered every 2 weeks (66 percent to 75 percent) and monthly (63 percent to 75 percent) when added to moderate- or high-intensity statin therapy. The additional LDL-C lowering seen with evolocumab was greater than that observed with ezetimibe (up to 24 percent reduction).

Evolocumab was well tolerated, with comparable rates of adverse events compared to placebo and ezetimibe during the 12-week treatment period.

“LAPLACE-2 is to our knowledge the first study to demonstrate that the addition of evolocumab results in similar percent reductions in LDL-C and achieved LDL-C levels regardless of stable baseline statin type, dose, or intensity, across 3 commonly prescribed statins and a broad range of doses,” the authors write.

“Further studies are needed to evaluate longer-term clinical outcomes and safety of this approach for LDL-C lowering.”

(doi:10.1001/jama.2014.4030; Available pre-embargo to the media at https://media.jamanetwork.com)

Editor’s Note: This trial was funded by Amgen Inc., which was responsible for the design and conduct of the study as well as data collection and interpretation, management, and analysis. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

# # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Daniel K. Benjamin Jr., M.D., Ph.D., call Sarah Avery at 919-660-1306 or email sarah.avery@duke.edu.

Use of the antifungal medication fluconazole for six weeks for extremely low birth-weight infants did not significantly reduce the risk of death or invasive candidiasis, a serious infection that occurs when candida (a type of fungus) enters the bloodstream and spreads through the body, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Invasive candidiasis is an important cause of infection in premature infants; despite treatment with antifungal therapy, invasive candidiasis has serious effects on premature infants, including severe neurodevelopmental impairment and death. Current recommendations include the use of fluconazole for prevention of this infection for infants with a birth weight of less than 1,000 grams (2.2 lbs.) who receive care in neonatal intensive care units (NICUs). However, most NICUs in the United States and the European Union have not uniformly adopted preventive use of fluconazole, based on controversies regarding high-risk patients, resistance, and safety, according to background information in the article.

Daniel K. Benjamin Jr., M.D., Ph.D., of Duke University, Durham, N.C., and colleagues evaluated the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low birth-weight infants (weighing less than 750 grams [1.7 lbs.] at birth). The study included 361 infants from 32 NICUs in the United States who were randomly assigned to receive either fluconazole (6mg/kg of body weight) or placebo twice weekly for 42 days.

The primary composite end point of death or invasive candidiasis by study day 49 was not statistically different between the 2 groups (fluconazole, 16 percent vs placebo, 21 percent). The percentage of infants who died prior to study day 49 was not different between the groups (14 percent vs 14 percent). Fewer infants developed definite or probable invasive candidiasis in the fluconazole (3 percent) vs in the placebo group (9 percent).

“Fluconazole prophylaxis compared with placebo was not associated with a statistically significant difference in the composite primary end point—death or definite or probable invasive candidiasis— although it was associated with a statistically significant reduction in the incidence of definite or probable candidiasis alone.  This study adds new evidence regarding the efficacy of fluconazole prophylaxis, but raises the question of whether prevention of invasive candidiasis translates into substantial improvements in the outcomes of prematurity.”

“Based on both the results of our study in NICUs with a low incidence of invasive candidiasis, and previous prophylaxis trials in high-incidence NICUs, the routine use of fluconazole prophylaxis should be limited to units with moderate-to-high incidence of invasive candidiasis. However, additional research is needed to precisely define the incidence at which the benefits of fluconazole prophylaxis outweigh the risks,” the authors write.

(doi:10.1001/jama.2014.2624; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Jorge A. Bezerra, M.D., call Nick Miller at 513-803-6035 or email nicholas.miller@cchmc.org.

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Biliary atresia progresses to end-stage liver disease (cirrhosis) in more than 70 percent of affected children and is the leading indication for pediatric liver transplantation in the world, accounting for about 50 percent of liver transplants in children. Hepatoportoenterostomy (surgery to improve bile drainage) results in successful bile drainage in only about half of patients with biliary atresia treated in the United States, underscoring the need for additional therapies to improve survival without liver transplantation, according to background information in the article. There have been conflicting reports regarding the effectiveness of the use of corticosteroids to improve bile flow following surgery.

Jorge A. Bezerra, M.D., of Cincinnati Children’s Hospital Medical Center, Cincinnati, and colleagues randomly assigned 140 infants (average age, 2.3 months) to receive high-dose steroid therapy or placebo following surgery to improve bile drainage.

The researchers found that the proportion of infants with improved bile drainage was not significantly improved by steroids at 6 months following surgery (58.6 percent of steroids group vs 48.6 percent of placebo group). The adjusted absolute risk difference was 8.7 percent.

Survival without liver transplantation at 2 years of age for infants treated with steroids was nearly identical to those who received placebo (58.7 percent vs. 59.4 percent). Serious adverse events were com­mon in both treatment groups (81.4 percent for steroids vs 80.0 percent for placebo); however, infants treated with steroids experienced their first serious adverse events earlier than those receiving placebo.

“Based on the strength of the evidence, the addition of high-dose steroids as an adjuvant [supplemental] treatment for infants with biliary atresia after hepatoportoenterostomy cannot be recommended,” the authors write.

(doi:10.1001/jama.2014.2623; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Flor M. Munoz, M.D., call Dipali Pathak at 713-798-4710 or email pathak@bcm.edu. To contact editorial co-author Kathryn M. Edwards, M.D., call Craig Boerner at 615-322-4747 or email craig.boerner@vanderbilt.edu.

A preliminary study finds that receipt of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in the third trimester of pregnancy did not increase the risk of adverse events for the mother or infant, according to a study in the May 7 issue of JAMA, a theme issue on child health. In addition, the authors found high concentrations of pertussis antibodies in infants during the first 2 months of life, a period during which infants are at the highest risk of pertussis-associated illness or death. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Pertussis is a highly contagious and potentially fatal vaccine-preventable disease that has re-emerged in the United States despite high childhood immunization rates. Infants younger than 6 months are at greatest risk of disease, hospitalization, and death and account for more than 90 percent of all pertussis-associated deaths in the United States. Infants too young to receive the primary diphtheria and tetanus toxoids and acellular pertussis (DTaP) immunization series (recommended at 2, 4, and 6 months of age) depend on maternal antibodies for protection against pertussis. However, pregnant women have very low concentrations of pertussis antibodies to transfer to their newborn at the time of delivery; maternal immunization with the Tdap vaccine could help prevent infant pertussis, according to background information in the article.

Flor M. Munoz, M.D., of the Baylor College of Medicine, Houston, and colleagues randomly assigned 48 women to receive the Tdap vaccine (n = 33) or placebo (n = 15) at 30 to 32 weeks’ gestation to evaluate the safety and immunogenicity (ability to produce an immune response) of the vaccine administered during pregnancy. Women who received placebo during pregnancy were given Tdap vaccine postpartum prior to hospital discharge, and women who received Tdap during pregnancy were given placebo postpartum.

The researchers found that injection site and systemic reactogenicity (adverse reactions) rates in pregnant women were not significantly different than those observed among postpartum or nonpregnant women. No Tdap-associated serious adverse events occurred in women or infants. Growth and development were similar in both infant groups. No cases of pertussis occurred.

Also, concentrations of vaccine-induced pertussis antibodies in infants born to mothers immunized with Tdap during pregnancy were significantly higher at birth and at age 2 months than in infants whose mothers were immunized postpartum.

In addition, maternal immunization with Tdap did not substantially alter infant responses to scheduled DTaP.

“Further research is needed to provide definitive evidence of the safety and efficacy of Tdap immunization during pregnancy,” the authors write.

(doi:10.1001/jama.2014.3633; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Maternal Pertussis Immunization – Can It Help Infants?

Although Tdap has an excellent safety record, future cohort or surveillance studies must continue to assess safety and immunogenicity of Tdap immunization during pregnancy, write Natalia Jimnez-Truque, M.S.C.I., Ph.D., and Kathryn M. Edwards, M.D., of Vanderbilt University Medical Center, Nashville, Tenn., in an accompanying editorial.

“Continued reporting of pertussis cases will also be necessary to assess the effectiveness of administering Tdap during pregnancy. In addition, the assessment of potential interference with DTaP and other vaccine antigens administered during infancy will require large prospective studies. Last, future research must address the safety and immunogenicity of repeated doses of Tdap during each pregnancy, because frequent immunization might lead to a blunted antibody response.”

(doi:10.1001/jama.2014.3555; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact corresponding author Sarah D. de Ferranti, M.D., M.P.H., call Rob Graham at 617-919-3110 or email Rob.graham@childrens.harvard.edu.

Although some guidelines recommend lipid screening for children and adolescents of certain ages, data indicate that only about 3 percent are having their cholesterol tested during health visits, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Abnormal lipid values occur in 1 in 5 U.S. children and adolescents, and are associated with cardiovascular disease in adulthood. Universal pediatric lipid screening is advised by the National Heart, Lung, and Blood Institute (NHLBI) for those ages 9 to 11 years and 17 to 21 years, in addition to the selective screening advised by the American Academy of Pediatrics (AAP) and the American Heart Association. In contrast, the U.S. Preventive Services Task Force (USPSTF) did not find sufficient evidence to recommend any pediatric lipid screening, according to background information in the article.

Samuel R. Vinci, B.A., of Boston Children’s Hospital, and colleagues examined rates and trends in cholesterol testing, including before and after the 2007 USPSTF and 2008 AAP cholesterol statements. For this analysis, the researchers used patient data from the National Ambulatory Medical Care Survey, which provides nationally representative estimates.

During the period from 1995 through 2010, clinicians ordered cholesterol testing at 3.4 percent of 10,159 health maintenance visits. Testing rates increased only slightly from 2.5 percent in 1995 to 3.2 percent in 2010. The authors note that applying the most recent 2011 NHLBI guidelines to 2009 U.S. census data, approximately 35 percent of patients would be eligible for lipid screening in any given year based on age (9-11 years and 17-21 years).

“Testing rates did not appear to increase after 2007-2008, perhaps reflecting the conflicting positions of the AAP and USPSTF,” the authors conclude.

(doi:10.1001/jama.2014.2410; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Sven Sandin, M.Sc., email Sven.Sandin@ki.se. To contact editorial co-author Diana E. Schendel, Ph.D., email diana.schendel@folkesundhed.au.dk.
 

The risk of autism may be influenced equally by genetic and environmental factors; in addition, a sibling of a family member with autism has a much higher risk for the disorder, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Autism spectrum disorder (ASD) affects almost 1 percent of all children born in the United States and is defined as impairment in social interaction and communication and the presence of restricted interests and repetitive behaviors. Autistic disorder (autism) is the most profound form of ASD, which aggregates in families (increased risk among members of the same family), but the individual risk and to what extent this is caused by genetic or environmental factors is uncertain, according to background information in the article.

Sven Sandin, M.Sc., of the Karolinska Institutet, Stockholm, Sweden, and colleagues estimated the heritability of ASD and risk among family members and assessed the importance of genetic vs. environmental factors by using data of all births in Sweden between 1982 and 2006 (n = 2,049,973). The researchers determined the relative recurrence risk (RRR), which is the relative risk of autism in a participant with a sibling or cousin who has the diagnosis (exposed) compared with the risk in a participant with no diagnosed family member (unexposed).

The study included 14,516 children with ASD, of whom 5,689 (39 percent) had a diagnosis of autistic disorder. The researchers found a 10-fold increased risk of recurrence among siblings of a family member with ASD; cousins had a 2-fold increased risk. This pattern was similar for autistic disorder but of slightly higher magnitude.

Among children born in Sweden, the heritability of ASD was estimated at approximately 50 percent, as was the environmental influence.

“These findings may inform the counseling of families with affected children,” the authors write.

(doi:10.1001/jama.2014.4144; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

There will also be an audio author interview available for this study at 3 p.m. CT Saturday, May 3, at JAMA.com.

Editorial: The Genetic and Environmental Contributions to Autism

Diana E. Schendel, Ph.D., of Aarhus University, Aarhus, Denmark, and colleagues write in an accompanying editorial that much remains to be understood regarding familial risk for autism.

“Future studies might consider risks from different combinations of diagnoses in the [family member with ASD] and sibling; for example, the risk of any ASD diagnosis in the sibling of a child diagnosed with autistic disorder, or other combinations of ASD-related or comorbid neurodevelopmental diagnoses (e.g., ASD-epilepsy combinations).”

“In conclusion, the work by Sandin et al supports appreciation of the importance of genetic factors in ASD and adds substantial impetus to the growing attention to environmental influences in ASD etiology.”

(doi:10.1001/jama.2014.3554; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Maria Makrides, B.Sc., B.N.D., Ph.D., email maria.makrides@health.sa.gov.au.

Although there are recommendations for pregnant women to increase their intake of the omega-3 fatty acid docosahexaenoic acid (DHA) to improve fetal brain development, a randomized trial finds that prenatal DHA supplementation did not result in improved cognitive, problem-solving or language abilities for children at four years of age, according to the study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Maria Makrides, B.Sc., B.N.D., Ph.D., of the South Australian Health and Medical Research Institute, Adelaide, Australia and colleagues conducted longer-term follow-up from a previously published study in which pregnant women received 800 mg/d of DHA or placebo. In the initial study, the researchers found that average cognitive, language, and motor scores did not differ between children at 18 months of age. For the follow-up study, outcomes were assessed at 4 years, a time point when any subtle effects on development should have emerged and can be more reliably assessed.

The majority (91.9 percent) of eligible families (DHA group, n = 313; control group, n = 333) participated in the follow-up. The authors found that measures of cognition, the ability to perform complex mental processing, language, and executive functioning (such as memory, reasoning, problem solving) did not differ significantly between groups.

“Our data do not support prenatal DHA supplementation to enhance early childhood development.”

(doi:10.1001/jama.2014.2194; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 3 P.M. (CT) SATURDAY, MAY 3, 2014

Media Advisory: To contact Dana Dabelea, M.D., Ph.D., call Tonya Ewers at 303-724-8573 or email tonya.ewers@ucdenver.edu.

In a study that included data from more than three million children and adolescents from diverse geographic regions of the United States, researchers found that the prevalence of both type 1 and type 2 diabetes increased significantly between 2001 and 2009, according to the study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Dana Dabelea, M.D., Ph.D., of the Colorado School of Public Health, Aurora, Colo., and Elizabeth J. Mayer-Davis, Ph.D., of the University of North Carolina, Chapel Hill, and colleagues with the SEARCH for Diabetes in Youth Study, examined whether the overall prevalence of type 1 and type 2 diabetes among U.S. youth has changed in recent years, and whether it changed by sex, age, and race/ethnicity. Despite concern about an “epidemic,” there have been limited data on trends regarding diabetes. “Understanding changes in prevalence according to population subgroups is important to inform clinicians about care that will be needed for the pediatric population living with diabetes and may provide direction for other studies designed to determine the causes of the observed changes,” the authors write.

The analysis included cases of physician-diagnosed type 1 diabetes in youth ages 0 through 19 years and type 2 diabetes in youth 10 through 19 years of age in 2001 and 2009.  The study population came from five centers located in California, Colorado, Ohio, South Carolina, and Washington state, as well as data from selected American Indian reservations in Arizona and New Mexico.

In 2001, the prevalence of type 1 diabetes among a population of 3.3 million was 1.48 per 1,000, which increased to 1.93 per 1,000 among 3.4 million youth in 2009, which, after adjustment, indicated an increase of 21 percent over the 8-year period. The greatest prevalence increase was observed in youth 15 through 19 years of age. Increases were observed in both sexes and in white, black, Hispanic, and Asian Pacific Islander youth. “Historically, type l diabetes has been considered a disease that affects primarily white youth; however, our findings highlight the increasing burden of type l diabetes experienced by youth of minority racial/ethnic groups as well,” the authors write.

The overall prevalence of type 2 diabetes for youth ages 10 to 19 years increased by an estimated 30.5 percent between 2001 and 2009 (among a population of 1.7 million and 1.8 million youth, respectively).  Increases occurred in white, Hispanic, and black youth, whereas no changes were found in Asian Pacific Islander and American Indian youth. A significant increase was seen in both sexes and all age-groups.

“The increases in prevalence reported herein are important because such youth with diabetes will enter adulthood with several years of disease duration, difficulty in treatment, an increased risk of early complications, and increased frequency of diabetes during reproductive years, which may further increase diabetes in the next generation,” the researchers write. “Further studies are required to determine the causes of these increases.”

(doi:10.1001/jama.2014.3201; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Saturday, May 3 at this link.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact James M. Chamberlain, M.D., call Joe Cantlupe at 202-476-4500 or email JCantlupe@childrensnational.org.

Although some studies have suggested that the drug lorazepam may be more effective or safer than the drug diazepam in treating a type of epileptic seizures among children, a randomized trial finds that lorazepam is not better at stopping seizures compared to diazepam, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.

Status epilepticus is a prolonged epileptic seizure or seizures that occurs approximately 10,000 times in children annually in the United States. Rapid control of status epilepticus is essential to avoid permanent injury and life-threatening complications such as respiratory failure. The Food and Drug Administration has approved diazepam, but not lorazepam, for the treatment of status epilepticus in children. Studies involving lorazepam have shown mixed results, according to background information in the article.

James M. Chamberlain, M.D., of the Children’s National Medical Center, Washington, D.C., and colleagues with the Pediatric Emergency Care Applied Research Network, randomly assigned 273 patients (age 3 months to younger than 18 years with convulsive status epilepticus) presenting to one of 11 pediatric emergency departments to receive diazepam or lorazepam intravenously.

The researchers found that the primary measure of effectiveness, cessation of status epilepticus for 10 minutes without recurrence within 30 minutes, occurred in 101 of 140 (72.1 percent) in the diazepam group and 97 of 133 (72.9 percent) in the lorazepam group. Twenty-six patients in each group required assisted ventilation (the primary safety outcome; 16.0 percent given diazepam and 17.6 percent given lorazepam).

There were no significant differences in other outcomes such as rates of seizure recurrence and time to cessation of convulsions, except that patients receiving lorazepam were more likely to experience sedation (67 percent vs 50 percent).

The authors write that the study results have important implications for both outside the hospital and emergency department care. “Diazepam can be stored without refrigeration and thus has been used as the treatment of choice in many prehospital systems. The results of this study do not support the superiority of lorazepam over diazepam as a first-line agent for pediatric status epilepticus.”

The researchers add that future trials should consider newer medications and novel interventions targeting those at highest risk for medication failure or respiratory depression.

(doi:10.1001/jama.2014.2625; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact Martin Ebinger, M.D., email martin.ebinger@charite.de.

Using an ambulance that included a computed tomography (CT) scanner, point-of-care laboratory, telemedicine connection and a specialized prehospital stroke team resulted in decreased time to treatment for ischemic stroke, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.

Stroke is a leading cause of death and disability. In acute ischemic stroke, thrombolysis (dissolving of blood clots) using intravenous tissue plasminogen activator (tPA) is the treatment of choice after excluding bleeding in the brain by imaging. Past studies have shown time-dependent benefits of tPA, with early treatment associated with better outcomes. Apart from delayed patient presentation, management inside and outside of the hospital contributes to treatment delays. Recent data from the United States indicate that less than 30 percent of patients have a door-to-needle time for receiving tPA within the recommended 60 minutes. A recent study reported time-savings for 12 tPA administrations performed in a special ambulance with a CT scanner and laboratory. Little is known about the overall effects of specialized ambulances for treating patients with stroke, according to background information in the article.

Martin Ebinger, M.D., of Charité–Universitätsmedizin Berlin, Germany, and colleagues conducted a study in which a specialized ambulance (Stroke Emergency Mobile [(STEMO]) was randomly assigned weeks when it was available for response in Berlin, which has an established stroke care system with 14 stroke units. The ambulance was equipped with a CT scanner, point-of-care laboratory, and telemedicine connection; a tool to help identify stroke at the dispatcher level; and a specialized prehospital stroke team, which included a neurologist, paramedic, and a radiology technician. If ischemic stroke was confirmed and contraindications excluded, thrombolysis was started before transport to hospital. The overall study population included 6,182 patients.

The researchers found that compared with control weeks, the average alarm-to-treatment (defined as when the dispatcher activated the alarm to tPA administration) time reduction was 25 minutes among patients receiving tPA after STEMO deployment. Also, the rate of tPA treatment in ischemic stroke was higher after STEMO deployment (33 percent) than during control weeks (21 percent).

STEMO deployment was not associated with increased risk for intracerebral hemorrhage or 7-day mortality.

The authors note that the effects found in this study have to be weighed against costs of the STEMO concept. Depending on the configuration of the vehicle, a single STEMO ambulance costs about $1.4 million. Cost-effectiveness analyses are currently under way.

“Our study showed that the ambulance-based thrombolysis was safe, reduced alarm-to-treatment time, and increased thrombolysis rates,” the researchers write. “Further studies are needed to assess the effects on clinical outcomes.”

(doi:10.1001/jama.2014.2850; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This study was funded by Zukunftsfonds Berlin with co-financing by the European Regional Development Fund. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact Winston Chiong, M.D., Ph.D., call Laura Kurtzman at 415-476-3163 or email Laura.Kurtzman@ucsf.edu.

The majority of adults surveyed indicated they would want administration of clot-dissolving medications if incapacitated by a stroke, a finding that supports clinicians’ use of this treatment if patient surrogates are not available to provide consent, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.

“In life-threatening emergencies involving incapacitated patients without surrogates, clinicians may intervene without obtaining informed consent, applying the presumption that reasonable people would consent to treatment in such circumstances. Whether this rationale applies to the treatment of acute ischemic stroke with intravenous thrombolysis [administration of clot-busting agent] is controversial because this intervention improves functional outcomes but is not life preserving. Nonetheless, the presumption of consent to thrombolysis for ischemic stroke has recently been endorsed by professional societies,” according to background information in the study.

Winston Chiong, M.D., Ph.D., of the University of California, San Francisco, and colleagues examined presumption of consent by comparing preferences for treatment of acute ischemic stroke with thrombolysis and treatment of sudden cardiac arrest with cardiopulmonary resuscitation (CPR; in which the presumption of consent is generally accepted) in a nationally representative sample of U.S. adults 50 years of age or older. The participants were randomly assigned to read 1 of 2 scenarios: in one they experienced a severe acute ischemic stroke and were brought to a hospital, and in the other they experienced an out-of-hospital cardiac arrest and were attended to by paramedics.

The stroke scenario included a graphical depiction of potential risks and benefits of treatment with thrombolysis. The cardiac arrest scenario included a similar depiction of potential outcomes after paramedic-initiated CPR. All participants were then asked whether they would want the treatment described.

The researchers found that 76.2 percent of older adults (419 of 545 participants) wanted thrombolysis for acute ischemic stroke and 75.9 percent of older adults (422 of 555 participants) wanted CPR for sudden cardiac arrest. Female sex, divorced marital status, and lower educational attainment predicted refusal of thrombolysis; poorer physical health, previous stroke, and possession of a health care advance directive predicted refusal of CPR.

“When an incapacitated older patient’s treatment preferences are unknown and surrogate decision makers are unavailable, there are equally strong empirical grounds for presuming individual consent to thrombolysis for stroke as for presuming individual consent to CPR. Because the presumption of consent is generally accepted for CPR, this finding provides empirical support for policy positions recently taken by professional societies that favor the use of thrombolysis for stroke in emergency circumstances under a presumption of consent,” the authors write.

(doi:10.1001/jama.2014.3302; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact Michael Wall, M.D., call Jennifer Brown at 319- 356-7124 or email jennifer-l-brown@uiowa.edu. To contact editorial author Jonathan C. Horton, M.D., Ph.D., call Juliana Bunim at 415-476-8810 or email juliana.bunim@ucsf.edu.
In patients with idiopathic intracranial hypertension and mild vision loss, the use of the drug acetazolamide, along with a low-sodium weight-reduction diet, resulted in modest improvement in vision, compared with diet alone, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.

Idiopathic intracranial hypertension (IIH) is a disorder primarily of overweight women of childbearing age, characterized by increased intracranial pressure with its associated signs and symptoms, including debilitating headaches and vision loss. Acetazolamide is commonly used to treat this condition, but strong evidence to support its use is lacking, according to background information in the article.

Michael Wall, M.D., of the University of Iowa, Iowa City, and colleagues with the NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, randomly assigned 165 participants with IIH and mild visual loss to receive acetazolamide or matching placebo for 6 months to determine its effect on reducing or reversing visual loss. All participants were also asked to follow a low-sodium weight-reduction diet.

The average improvement in perimetric mean deviation (PMD; a measure of global visual field loss) was greater with acetazolamide than with placebo. In addition, there were improvements in papilledema (optic disc swelling) and vision-related quality of life with acetazolamide. Participants who received acetazolamide also experienced a greater reduction in weight.

There were few unexpected adverse events associated with acetazolamide use.

“This is the first multicenter, double-blind, randomized, controlled clinical trial, to our knowledge, to show that acetazolamide improves visual outcome in IIH,” the authors write. “The clinical importance of this improvement remains to be determined.”

(doi:10.1001/jama.2014.3312; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 Editorial: Acetazolamide for Pseudotumor Cerebri – Evidence From the NORDIC Trial

“The obesity epidemic has increased the prevalence of pseudotumor cerebri [idiopathic intracranial hypertension]. Consequently, the health care costs associated with the treatment of this disease have escalated sharply,” writes Jonathan C. Horton, M.D., Ph.D., of the University of California, San Francisco, in an accompanying editorial.

“The NORDIC trial has provided solid evidence that patients can be treated effectively by weight loss and acetazolamide. Their visual acuity and visual fields should be tested regularly, at a frequency that depends on the severity of their condition. If vision is failing despite medical treatment, rapid surgical intervention is necessary.”

“Additional studies are needed to refine the management of patients with pseudotumor cerebri to ensure preservation of visual function.”

(doi:10.1001/jama.2014.3325; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including financial disclosures, funding and support, etc.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact Rustam Al-Shahi Salman, Ph.D., email Jen Middleton at jen.middleton@ed.ac.uk.

Patients with arteriovenous malformations (abnormal connection between arteries and veins) in the brain that have not ruptured had a lower risk of stroke or death for up to 12 years if they received conservative management of the condition compared to an interventional treatment, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.

Interventional treatment for brain arteriovenous malformations (bAVMs) with procedures such as neurosurgical excision, endovascular embolization, or stereotactic radiosurgery can be used alone or in combination to attempt to obliterate bAVMs. Because interventions may have complications and the untreated clinical course of unruptured bAVMs can be benign, some patients choose conservative management (no intervention). Guidelines have endorsed both intervention and conservative management for unruptured bAVMs. Whether conservative management is superior to interventional treatment for unruptured bAVMs is uncertain because of the lack of long-term experience, according to background information in the article.

Rustam Al-Shahi Salman, Ph.D., of the University of Edinburgh, Scotland, and colleagues with the Scottish Audit of Intracranial Vascular Malformations Collaborators, studied 204 residents of Scotland (16 years of age or older) who were first diagnosed as having an unruptured bAVM during 1999-2003 or 2006-2010 and followed over time. The researchers analyzed the outcomes for patients who received conservative management (no intervention; medications for seizures) or an intervention (any endovascular embolization, neurosurgical excision, or stereotactic radiosurgery alone or in combination).

Of the 204 patients, 103 underwent some type of intervention. Those who underwent intervention were younger, more likely to have presented with seizure, and less likely to have large bAVMs than patients managed conservatively. During a median (midpoint) follow-up of 6.9 years, the rate of progression to sustained disability or death was lower with conservative management during the first 4 years of follow-up, but rates were similar thereafter. The rate of nonfatal stroke or death (due to the bAVM or intervention) was lower with conservative management during 12 years of follow-up (14 vs 38 events).

“The similarity of the results of this observational study and ARUBA [a randomized clinical trial that examined this issue] and the persistent difference between the outcome of conservative management and intervention during 12-year follow-up in our study support the superiority of conservative management to intervention for unruptured bAVMs, which may deter some patients and physicians from intervention,” the authors write.

“Long-term follow-up in both this study and the ARUBA trial is needed to establish whether the superiority of conservative management will persist or change.”

(doi:10.1001/jama.2014.3200; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 22, 2014

Media Advisory: To contact Gregg C. Fonarow, M.D., call Kim Irwin at 310-794-2262 or email kirwin@mednet.ucla.edu. To contact editorial author James C. Grotta, M.D., call Alex Rodriguez Loessin at 713-704-1222 or email alex.loessin@memorialhermann.org.
In a study that included more than 71,000 stroke patients, implementation of a quality initiative was associated with improvement in the time to treatment and a lower risk of in-hospital death, intracranial hemorrhage (bleeding in the brain), and an increase in the portion of patients discharged to their home, according to the study appearing in the April 23/30 issue of JAMA, a neurology theme issue.

Intravenous tissue plasminogen activator (tPA; an enzyme that helps dissolve clots) reduces long-term disability when administered early to eligible patients with acute ischemic stroke. These benefits, however, are highly time dependent. Because of the importance of rapid treatment, national guidelines recommend that hospitals complete the evaluation of patients with acute ischemic stroke and begin intravenous tPA therapy for eligible patients within 60 minutes of hospital arrival. However, prior studies demonstrate that less than one-third of patients are treated within the recommended time frame, and that this measure has improved minimally over time, according to background information in the article.

Gregg C. Fonarow, M.D., of the University of California, Los Angeles, and colleagues examined the results of a national quality improvement initiative (Target: Stroke), that was launched to increase timely stroke care. The initiative included 10 key strategies to achieve faster door-to-needle (DTN) times for tPA administration, provided clinical decision support tools, facilitated hospital participation, and encouraged sharing of best practices. This study included 71,169 patients with acute ischemic stroke treated with tPA from 1,030 participating hospitals.

The researchers found that measures of DTN time for tPA administration improved significantly during the postintervention period compared with the preintervention period as did clinical outcomes. The median (midpoint) door-to-needle time for tPA administration for the preintervention period was 77 minutes, which decreased to 67 minutes for the entire postintervention period. Door-to-needle times for tPA administration of 60 minutes or less increased from 26.5 percent to 41.3 percent (and from 29.6 percent to 53.3 percent at the end of each intervention period). Other improvements included in-hospital deaths (9.9 percent to 8.3 percent); discharge to home (38 percent to 43 percent); independence with walking (42 percent to 45 percent); and symptomatic intracranial hemorrhage within 36 hours (5.7 percent to 4.7 percent).

There was also a more than 4-fold increase in the yearly rate of improvement in the proportion of patients with door-to-needle times of 60 minutes or less after initiation of the intervention.

“These findings further reinforce the importance and clinical benefits of more rapid administration of intravenous tPA,” the authors write.

(doi:10.1001/jama.2014.3203; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, April 22 at this link.

Editorial: tPA for Stroke – Important Progress in Achieving Faster Treatment

In an accompanying editorial, James C. Grotta, M.D., of the Memorial Hermann Hospital, Clinical Innovation and Research Institute, Houston, comments on the two studies in this issue of JAMA regarding improving the time of tPA administration for stroke.

“Whatever benefits occur from interventions to achieve more rapid tPA treatment for patients with acute stroke need to be balanced against the costs to establish and maintain them, both to the payers who will pay for them and the hospital and emergency medical services organizations that will implement and operate them. This issue requires carefully constructed cost-effectiveness studies carried out in the environments where the interventions will be implemented; these are likely to differ between cities in the United States and in other countries and between rural and urban areas.”

“The studies by Fonarow et al and Ebinger et al in this issue of JAMA indicate exactly where and how to direct efforts in improving treatment outcomes for patients with acute ischemic stroke—namely by reducing time from symptom onset to treatment.”

(doi:10.1001/jama.2014.3322; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Grotta reported having received consulting fees from Specialists on Call, Frazer, and Stryker and grants from Genentech, Lundbeck, Haemonetics, Covidien, and Zolt.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 15, 2014

Media Advisory: To contact Donald S. A. McLeod, F.R.A.C.P., M.P.H., email donald.mcleod@qimrberghofer.edu.au.

An analysis that included active military personnel finds that the rate of the thyroid disorder Graves disease is more common among blacks and Asian/Pacific Islanders compared with whites, according to a study in the April 16 issue of JAMA.

Donald S. A. McLeod, F.R.A.C.P., M.P.H., of the QIMR Berghofer Medical Research Institute, Queensland, Australia and colleagues studied all U.S. active duty military, ages 20 to 54 years, from January 1997 to December 2011 to determine the rate of Graves disease and Hashimoto thyroiditis (a progressive autoimmune disease of the thyroid gland) by race/ethnicity. Cases were identified from data in the Defense Medical Surveillance System, which maintains comprehensive records of inpatient and outpatient medical diagnoses among all active-duty military personnel. The relationship between Graves disease and race/ethnicity has previously not been known.

During the study period there were 1,378 cases of Graves disease in women and 1,388 cases in men and 758 cases of Hashimoto thyroiditis in women and 548 cases in men. Compared with whites, the incident rates for Graves disease was significantly higher among blacks and Asian/Pacific Islanders. In contrast, Hashimoto thyroiditis incidence was highest in whites and lowest in blacks and Asian/Pacific Islanders.

The authors write that the differences in incidence by race/ethnicity found in this study may be due to different environmental exposures, genetics, or a combination of both.

(doi:10.1001/jama.2013.285606; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: A Cancer Council Queensland PhD scholarship helped support Dr. McLeod. The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Cooper reported receiving royalties for serving as an editor to Up-to-Date. No other disclosures were reported.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 15, 2014

Media Advisory: To contact Dagfinn Aune, M.S., email d.aune@imperial.ac.uk.
Higher maternal body mass index (BMI) before or in early pregnancy is associated with an increased risk of fetal death, stillbirth, and infant death, with women who are severely obese having the greatest risk of these outcomes from their pregnancy, according to a study in the April 16 issue of JAMA.

Worldwide, approximately 2.7 million stillbirths occurred in 2008. In addition, an estimated 3.6 million neonatal deaths (death following live birth of an infant but before age 28 days) occur each year. Several studies have suggested that greater maternal body mass index (BMI) before or during early pregnancy is associated with an increased risk of fetal death, stillbirth, perinatal death (stillbirth and early neonatal death), neonatal death, and infant death, although not all studies have found a significant association. The optimal prepregnancy BMI to prevent fetal and infant death has not been established, according to background information in the article.

Dagfinn Aune, M.S., of Imperial College London, and colleagues conducted a review and meta-analysis to examine the association between maternal BMI (before or in early pregnancy) and risk of fetal death, stillbirth, and infant death. After a search of the medical literature, the researchers identified 38 studies that met criteria for inclusion in the meta-analysis, which included more than 10,147 fetal deaths, more than 16,274 stillbirths, more than 4,311 perinatal deaths, 11,294 neonatal deaths, and 4,983 infant deaths.

The researchers found that even modest increases in maternal BMI were associated with increased risk of fetal death, stillbirth, neonatal death, perinatal death, and infant death. The greatest risk was observed in the category of severely obese women; women with a BMI of 40 had an approximate 2- to 3-fold increase in risk of these outcomes vs. women with a BMI of 20.

The authors suggest that several biological mechanisms could explain the association found in this study, including that being overweight or obese has been associated with increased risk of preeclampsia, gestational diabetes, type 2 diabetes, gestational hypertension, and congenital anomalies, conditions that have been strongly associated with risk of fetal and infant death. “… further studies are needed to investigate the mechanisms involved.”

“Weight management guidelines for women who plan pregnancies should take these findings into consideration to reduce the burden of fetal deaths, stillbirths, and infant deaths.”

(doi:10.1001/jama.2014.2269; Available pre-embargo to the media at https://media.jamanetwork.com)

Editor’s Note: This project was supported by a grant from the Norwegian SIDS and Stillbirth Society, Oslo, Norway. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 8, 2014

Media Advisory: To contact Steven D. Pearson, M.D., M.Sc., call Molly Hooven at 301-594-5789 or email Molly.Hooven@nih.gov.
In the creation of lists by specialty societies of medical services deemed least beneficial (the “Choosing Wisely” initiative), inclusion was often justified by evidence suggesting no additional benefit with higher risk, higher cost, or both, compared with other options, according to a study in the April 9 issue of JAMA.

“Aiming to reduce wasteful medical care, the American Board of Internal Medicine Foundation’s Choosing Wisely initiative asks leading physician specialty societies to create a ‘Top 5’ list of medical services that provide no overall benefit to patients in most situations. As of August 2013, 25 participating specialty societies had produced 1 or more Top 5 lists containing a total of 135 services,” according to background information in the article.

Catherine Gliwa, B.A., and Steven D. Pearson, M.D., M.Sc., of the National Institutes of Health, Bethesda, Md., evaluated the role that evidence related to benefits, risks, and costs plays in selecting a service for the Top 5 lists. “As Choosing Wisely continues to grow, clarity on the evidentiary justifications for the lists will be crucial for the overall credibility of the campaign,” they write. Using information provided by the specialty societies, the authors created categories based on the level of certainty of evidence regarding risks and benefits, how the risks and benefits of the service compare with other alternatives, and the comparative cost or cost-effectiveness of the service.

Of the 135 services identified, 36 percent were for diagnosis or monitoring; 34 percent for treatment; and 30 percent for population screening. Most services were included in the Top 5 lists based on evidence that demonstrates equivalent but not superior benefit with higher risk or higher costs, or both, compared with other options.  The second most common rationale was that there was not enough evidence to evaluate benefit for use of the service beyond the established indications, frequency, intensity, or dosage.

The authors assessed the rationales for selecting all 135 services.  Overall, 49 percent mentioned greater risks to patients, 24 percent mentioned higher costs, 16 percent mentioned both greater risk and higher cost, and 42 percent mentioned neither. Of the 25 specialty societies, 60 percent had at least 1 service whose inclusion was justified in part by higher costs.

“Our data show that the issue of cost was almost always raised in the context of a service being judged as good as other options but more expensive. We believe that specialty societies should seek greater opportunities to include within their Top 5 lists services that offer only small incremental benefits at much higher prices,” the authors write.

“Specialty societies can enhance trust in the Choosing Wisely campaign by defining more clearly the types of potentially wasteful medical care they seek to eliminate, and by providing a clear evidentiary justification for the selection of each service.”

(doi:10.1001/jama.2013.285362; Available pre-embargo to the media at https://media.jamanetwork.com)

Editor’s Note: This research was supported by the Intramural Research Program of the National Institutes of Health. The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 8, 2014

Media Advisory: To contact corresponding author Dong-Wan Kim, M.D., Ph.D., email kimdw@snu.ac.kr.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene. These drug-sensitive mutations are found in about 10 percent of Western patients and almost 50 percent of Asian patients with NSCLC. However, a majority of patients with advanced NSCLC worldwide do not have tumors with these mutations (known as wild-type [WT]; no mutation detected within the gene). Studies have shown that TKI treatment is better than conventional chemotherapy in terms of progression-free survival (PFS) among patients with these EGFR mutations; it is not clear that EGFR TKIs are as effective as standard chemotherapy in patients without EGFR mutations, according to background information in the article

June-Koo Lee, M.D., of Seoul National University Hospital, Seoul, Republic of Korea, and colleagues performed a meta-analysis of randomized controlled trials that compared first-generation EGFR TKI (erlotinib and gefitinib) treatment with conventional chemotherapy in patients with advanced NSCLC without mutation of the EGFR gene. The authors identified 11 randomized controlled trials, with 1,605 patients with WT EGFR, which met criteria for inclusion in the meta-analysis.

The results indicated that chemotherapy was associated with longer PFS compared with EGFR TKI in patients with WT tumors. For a median (midpoint) PFS of 6.4 months in patients treated with standard chemotherapy, the corresponding reduction of PFS in patient receiving EGFR TKI would be 1.9 months.

The objective response rate (defined as the proportion of complete response and partial responses among all evaluable patients) was also higher with chemotherapy (92/549, 16.8 percent) compared with TKI (39/540, 7.2 percent). However, the overall survival did not differ between the two groups.

“… this study suggests that, in patients with WT EGFR tumors, conventional chemotherapy could be a preferable treatment option over EGFR TKI, although this recommendation cannot be conclusive because the overall comparisons were not based on randomization. Furthermore, the toxicity outcome was not assessed,” the authors write.

(doi:10.1001/jama.2014.3314; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This work was supported in part by National Research Foundation of Korea grants funded by the Korean government. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

# # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 1, 2014

Media Advisory: To contact corresponding author Walid F. Gellad, M.D., M.P.H., call Allison Hydzik at 412-647-9975 or email hydzikam@upmc.edu.
About 40 percent of pharmaceutical company boards of directors examined had at least one member who held a leadership position at an academic medical center, with annual compensation for these positions averaging approximately $300,000, according to a study in the April 2 issue of JAMA.

“Financial relationships between the pharmaceutical industry and physicians have come under increased scrutiny. Less attention has been paid to relationships between industry and the leadership of academic medical centers (AMCs), who wield considerable influence over research, clinical, and educational missions. When AMC leaders serve on pharmaceutical company boards, they hold a fiduciary responsibility to shareholders to promote the financial success of the company, which may conflict or compete with institutional oversight responsibilities and individual clinical and research practices,” according to background information in the article.

Timothy S. Anderson, M.D., of the University of Pittsburgh Medical Center, and colleagues examined how often AMC leaders served on the boards of directors for pharmaceutical companies. Data on board composition and academic positions were collected in January 2013 from the websites of the 50 largest pharmaceutical companies based on 2012 global prescription drug sales. Financial compensation information was collected from company proxy statements and from shareholder reports. AMCs were defined as U.S. medical schools, health professional schools, teaching hospitals, and health care systems; leadership positions included CEOs, clinical department chairs, division directors, medical school deans, and hospital boards of directors, in addition to university presidents and boards of directors.

Of the 50 companies examined, 3 private companies lacked public data on governance. Nineteen of 47 (40 percent) companies had at least 1 board member who also held a leadership position at an AMC, including 16 of 17 (94 percent) U.S. companies. Forty-one board members held AMC leadership positions in 2012, receiving an average financial compensation for board membership of $312,564 (excluding the 6 industry executives). Eighteen industry board members (3 percent of all board members) held 21 clinical or administrative leadership positions, including 2 university presidents, 6 deans, 6 hospital or health system executive officers, and 7 clinical department chairs or center directors.

The authors note that they “do not make any conclusions about whether specifically identified relationships led to actual, rather than potential, conflicts of interest.”

“However, given the magnitude of competing priorities between academic institutions and pharmaceutical companies, dual leadership roles cannot simply be managed by internal disclosure. These relationships present potentially far-reaching consequences beyond those created when individual physicians consult with industry or receive gifts.”

(doi:10.1001/jama.2013.284925; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 1, 2014

Media Advisory: To contact corresponding author Mary A.M. Rogers, Ph.D., call Beata Mostafavi at 734- 764-2220 or email bmostafa@umich.edu. To contact editorial author Jeffrey L. Carson, M.D., call Jennifer Forbes at 732-235-6356 or email jenn.forbes@rwjms.rutgers.edu.

Restricting red blood cell (RBC) transfusions among hospitalized patients to those with hemoglobin (the iron-containing protein in RBCs) measures below a certain level is associated with a lower risk of health care-associated infections, according to a study in the April 2 issue of JAMA.

Efforts to prevent health care-associated infection are among the priorities for the U.S. Department of Health and Human Services. The estimated annual direct medical costs of health care-associated infections to U.S. hospitals ranges from $28 billion to $45 billion, with about 1 in every 20 inpatients developing an infection related to their hospital care. Transfusion of RBCs is a common inpatient therapy, with approximately 14 million units transfused in 2011 in the United States, according to background information in the article. One potential approach to reducing the risk of infection associated with transfusions is lowering the hemoglobin thresholds (levels) at which RBC transfusions are indicated, so-called restrictive threshold strategies. The association between RBC transfusion strategies and health care-associated infection is not fully understood.

Jeffrey M. Rohde, M.D., of the University of Michigan, Ann Arbor, and colleagues compared restrictive vs liberal RBC transfusion strategies to evaluate their association with the risk of health care-associated infection. The study consisted of a review and meta-analysis of the data from 21 randomized trials with 8,735 patients who underwent transfusion; 18 trials (n = 7,593 patients) contained sufficient information for inclusion in the meta-analyses. The main outcomes measured for the analysis were the incidence of health care-associated infection such as pneumonia, mediastinitis (inflammation of tissue in the chest cavity), wound infection, and sepsis.

The researchers found that for those patients receiving the restrictive transfusion strategies, the risk of infection (for all serious infections) was 11.8 percent, and for patients receiving the liberal transfusion strategies, was 16.9 percent. Even with a reduction in the level of white blood cells (via the processing of blood), the risk of infection remained reduced with a restrictive strategy. The meta-analysis of randomized trials suggested that for every 1,000 patients in which RBC transfusion is under consideration, 26 could potentially be spared an infection if restrictive strategies were used.

The authors found no significant differences in the incidence of infection by RBC threshold for patients with cardiac disease, the critically ill, those with acute upper gastrointestinal bleeding, or for infants with low birth weight. The risk of infection was lower in patients undergoing orthopedic surgery or with sepsis and who received a restrictive transfusion strategy.

The authors write that the results of this review provide further support to a recent systematic review and clinical practice guideline put forth by the AABB (formerly the American Association of Blood Banks), that recommends adherence to a restrictive transfusion strategy for the majority of hospitalized patients and lists specific hemoglobin-based recommendations for different patient populations.

(doi:10.1001/jama.2014.2726; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This work was funded by a grant from the National Heart, Lung, and Blood Institute. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

Editorial: Blood Transfusion and Risk of Infection – New Convincing Evidence

Jeffrey L. Carson, M.D., of the Rutgers Robert Wood Johnson Medical School, New Brunswick, N.J., comments on this study in accompanying editorial.

“The only outcome evaluated in the report by Rohde et al was infection risk. However, other important outcomes such as mortality, myocardial infarction, and function should be considered in the overall risk-benefit analysis of transfusion.”

“The study by Rohde et al confirms another potential adverse outcome associated with transfusion: serious infectious disease. Clinical trials are needed to establish the optimal transfusion thresholds, to provide additional information about the risks and benefits of RBC transfusion, and to determine how best to use RBC transfusion.”

(doi:10.1001/jama.2014.2727; Available pre-embargo to the media at https://media.jamanetwork.com)

Editor’s Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Carson reports serving as a consultant to Cerus for a trial unrelated to this article and reports grant funding to his institution from the National Institutes of Health.

 # # #

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, APRIL 1, 2014

Media Advisory: To contact Thomas M. Pisansky, M.D., call Joe Dangor at 507-266-0696 or email dangor.yusuf@mayo.edu.
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA.

Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment. An estimated 40 percent of men report ED after radiation therapy, and half of all men use erectile aids following this therapy. Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, but its role as a preventive agent has not been determined, according to background information in the article.

Thomas M. Pisansky, M.D., of the Mayo Clinic, Rochester, Minn., and colleagues with the Radiation Therapy Oncology Group, randomly assigned 242 men with prostate cancer to receive tadalafil (5 mg) or placebo daily for 24 weeks starting with radiation therapy (either with external radiotherapy [63 percent] or brachytherapy [37 percent]). The study was conducted at 76 sites in the United States and Canada; participants were recruited between November 2009 and February 2012, with follow-up through March 2013.

Between weeks 28 and 30 after the start of radiation therapy, among evaluable participants, 79 percent who received tadalafil retained erectile function compared with 74 percent who received placebo, an absolute difference of 5 percent. A significant difference between groups was also not observed at 1 year (72 percent vs 71 percent). Tadalafil was not associated with improved overall sexual function or satisfaction, and partners of men assigned tadalafil noted no significant effect on sexual satisfaction.

“These findings do not support the scheduled once-daily use of tadalafil to prevent ED in men undergoing radiotherapy for localized prostate cancer,” the authors write.

They add that alternative strategies to prevent ED in this context appear warranted, including different dosing or further refinements of radiation therapy delivery methods.

(doi:10.1001/jama.2014.2626; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This trial was conducted by the Radiation Therapy Oncology Group, which was supported by grants from the National Cancer Institute and by Eli Lilly & Co. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 7 A.M. (CT) SUNDAY, MARCH 30, 2014

Media Advisory: To contact A. Michael Lincoff, M.D., call Wyatt DuBois at 216-904-3344 or email DUBOISW@ccf.org.

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

Cardiovascular disease remains the dominant cause of death among patients with type 2 diabetes. No drug therapy specifically directed against diabetes nor strategy for tight glucose control has been shown to unequivocally reduce the rate of cardiovascular complications in this population, according to background information in the article. In phase 2 trials, aleglitazar significantly reduced glycated hemoglobin levels (measure of blood glucose over an extended period of time), triglycerides, and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol (HDL-C).

A. Michael Lincoff, M.D., of the Cleveland Clinic, and colleagues conducted a phase 3 trial in which 7,226 patients hospitalized for heart attack or unstable angina with type 2 diabetes were randomly assigned to receive aleglitazar or placebo daily. The AleCardio trial was conducted in 720 hospitals in 26 countries throughout North America, Latin America, Europe, and Asia-Pacific regions.

The trial was terminated early (July 2013) after an average follow-up of 104 weeks, due to lack of efficacy and a higher rate of adverse events in the aleglitazar group.

The researchers found that although aleglitazar reduced glycated hemoglobin and improved serum HDL-C and triglyceride levels, the drug did not decrease the time to cardiovascular death, nonfatal heart attack, or nonfatal stroke (primary end points). These events occurred in 344 patients (9.5 percent) in the aleglitazar group and 360 patients (10.0 percent) in the placebo group.

Aleglitazar use was associated with increased risk of kidney abnormalities, bone fractures, gastrointestinal bleeding, and hypoglycemia (low blood sugars).

“These findings do not support the use of aleglitazar in this setting with a goal of reducing cardiovascular risk,” the authors conclude.

(doi:10.1001/jama.2014.3321 Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 9:45 A.M. (CT) MONDAY, MARCH 31, 2014

Media Advisory: To contact corresponding author Takeshi Kimura, M.D., email taketaka@kuhp.kyoto-u.ac.jp.

A comparison of the safety of biodegradable polymer biolimus-eluting stents vs durable polymer everolimus-eluting stents finds similar outcomes for measures including death and heart attack after two years, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

Recent studies have raised concerns about the safety of biodegradable polymer drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES). The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a study evaluating the efficacy and safety of biodegradable polymer biolimus-eluting stents (BP-BES) vs. DP-EES. The primary efficacy outcome of target-lesion revascularization (restoration of blood flow in coronary arteries) at 1 year demonstrated noninferiority (not worse than) of BP-BES compared with DP-EES. However, the advantages of BP-BES could emerge beyond 1 year when polymer has fully degraded, according to background information in the article. Masahiro Natsuaki, M.D., of Saiseikai Fukuoka General Hospital, Fukuoka, Japan, and colleagues examined outcomes of this trial after two years.

Of 3,235 patients, 1,617 were randomly assigned to receive BP-BES and 1,618 to DP-EES. The researchers found that treatment outcomes with BP-BES were noninferior to DP-EES for death or heart attack (7.8 percent vs 7.7 percent, respectively) and target-lesion revascularization (TLR) (6.2 percent vs 6.0 percent). The rates of death or heart attack and TLR were not significantly different between the groups at 2 years.

“In NEXT, the safety and efficacy outcomes of BP-BES were noninferior to those of DP-EES at 2 years. However, 2 years is not long enough to confirm the long-term safety of BP-BES, and the study was underpowered for the interim analysis. Follow-up at 3 years will be important,” the authors write.

(doi:10.1001/jama.2014.3584 Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 7 A.M. (CT) MONDAY, MARCH 31, 2014

Media Advisory: To contact corresponding author Iwan C.C. van der Horst, M.D., Ph.D., email i.c.c.van.der.horst@umcg.nl.
Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favorable effects on ventricular (heart) function, among patients without diabetes who underwent percutaneous coronary intervention (PCI; a procedure such as stent placement used to open narrowed coronary arteries) for ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), treatment with metformin did not result in improved ventricular function, according to a JAMA study released online to coincide with its presentation at the 2014 American College of Cardiology Scientific Sessions.

Treatment for STEMI includes immediate treatment with anticlotting medications and PCI to restore coronary blood flow. STEMI results in left ventricular dysfunction (decreased pump function) in up to 50 percent of patients, and approximately 20 percent to 40 percent of patients develop heart failure sometime after STEMI; heart failure after STEMI is associated with a 3 to 4 times higher risk of death. Left ventricular dysfunction is regarded as the strongest predictor for adverse outcome after STEMI, according to background information in the article.

Chris P. H. Lexis, M.D., of the University of Groningen, Groningen, the Netherlands, and colleagues randomly assigned 380 patients who underwent PCI for STEMI to receive metformin hydrochloride or placebo twice daily for 4 months to determine whether metformin helps preserve left ventricular function after STEMI in patients without diabetes. Left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps blood with each contraction) was assessed by magnetic resonance imaging.

Left ventricular ejection fraction 4 months after beginning the study did not differ between the metformin group (53.1 percent) and the placebo group (54.8 percent). In addition, N-terminal pro-brain natriuretic peptide level (a cardiac biomarker) was not different between the 2 groups.

Major adverse cardiac events were observed in 6 patients (3.1 percent) in the metformin group and in 2 patients (1.1 percent) in the placebo group.

“Because left ventricular function is currently regarded as the most important predictor of morbidity and mortality after STEMI, it is unlikely that metformin will have a significant effect on long-term outcome after STEMI in patients without diabetes,” the authors write.

“The present findings do not support the use of metformin in this setting.”

(doi:10.1001/jama.2014.3315 Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This study was supported by a grant from ZonMw, the Netherlands Organization for Health Research and Development, The Hague, the Netherlands. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 7 A.M. (CT) SUNDAY, MARCH 30, 2014

Media Advisory: To contact Mohamed Abdel-Wahab, M.D., email mohamed.abdel-wahab@segebergerkliniken.de. To contact editorial co-author E. Murat Tuzcu, M.D., call Wyatt DuBois at 216-904-3344 or email DUBOISW@ccf.org.
Among patients undergoing aortic valve replacement using a catheter tube, a comparison of two types of heart valve technologies, balloon-expandable or self-expandable valve systems, found a greater rate of device success with the balloon-expandable valve, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

Transcatheter aortic valve replacement (TAVR) has emerged as a new option for patients with severe narrowing of the aortic valve and as an effective alternative treatment method to surgical aortic valve replacement in selected high-risk patients. Different from surgery, transcatheter placement (via the patient’s groin) of aortic valve prostheses requires either a self-expandable or balloon-expandable system. A direct comparison of these 2 systems has not been previously performed, according to background information in the article.

Mohamed Abdel-Wahab, M.D., of the Segeberger Kliniken, Bad Segeberg, Germany, and colleagues with the CHOICE trial, randomly assigned patients with aortic stenosis (narrowing) who met other criteria to receive either a balloon-expandable valve (n = 121) or self-expandable valve (n = 120). Device success was defined by several measures, including successful vascular access and deployment of the device and retrieval of the delivery system, correct position of the device, and performance of the heart valve without moderate or severe regurgitation (backflow of blood through the valve).

The researchers found that device success occurred in 116 of 121 patients (95.9 percent) in the balloon-expandable group and 93 of 120 patients (77.5 percent) of patients in the self-expandable group. This difference was attributed to a lower frequency of more-than-mild aortic regurgitation (4.1 percent vs 18.3 percent) and the less frequent need for implanting more than 1 valve (0.8 percent vs 5.8 percent) in the balloon-expandable valve group.

Bleeding and vascular complications were not significantly different between groups. Cardiovascular mortality at 30 days was 4.1 percent in the balloon-expandable valve group and 4.3 percent in the self-expandable valve group.  Need for placement of a new permanent pacemaker was less frequent in the balloon-expandable valve group.

“With an accumulating body of evidence linking more-than-mild aortic regurgitation and consequently device failure with a worse clinical outcome after transcatheter aortic valve replacement, the findings of the CHOICE trial may have important clinical implications. Notably, at short-term follow-up, improvement of heart failure symptoms was more frequently observed with the balloon-expandable valve, whereas minor stroke rates were numerically higher. Nevertheless, long-term follow-up of the CHOICE population should be awaited to determine whether the observed differences in device success will translate into a clinically relevant overall benefit for the balloon-expandable valve,” the authors write.

(doi:10.1001/jama.2014.3316; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This trial was sponsored by the Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 Editorial: Selection of Valves for TAVR – Is the CHOICE Clear?

Further investigation is needed to determine which valve examined in this study will provide better long-term survival rate and better quality of life, write E. Murat Tuzcu, M.D., and Samir R. Kapadia, M.D., of the Cleveland Clinic, in an accompanying editorial.

“Continued efforts at understanding the risks and benefits of TAVR particularly in relation to patient characteristics, and long term outcomes are imperative for continued progress and refinement of these revolutionary devices. Additional rigorous randomized trials, like the CHOICE trial, will provide the quality of evidence necessary to ensure optimal use and optimal patient outcomes from TAVR.”

(doi:10.1001/jama.2014.3317; Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: Please see the article for additional information, including financial disclosures, funding and support, etc.

 # # #

EMBARGOED FOR EARLY RELEASE: 1 P.M. (CT) SATURDAY, MARCH 29, 2014

Media Advisory: To contact Paul Muntner, Ph.D., call Nicole Wyatt at 205-934-8938 or email nwyatt@uab.edu.
In an analysis of almost 11,000 patients, an assessment of equations that help guide whether a patient should begin taking a statin (cholesterol lowering medication) found that observed and predicted 5-year atherosclerotic cardiovascular disease risks were similar, suggesting that these equations are helpful for clinical decision making, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

The American College of Cardiology (ACC) and the American Heart Association (AHA) recently published the 2013 Guideline on the Assessment of Cardiovascular Risk. As part of this guideline, a group of experts developed the Pooled Cohort risk equations, which were designed to estimate 10-year risk for nonfatal myocardial infarction (MI; heart attack), coronary heart disease (CHD) death, and nonfatal or fatal stroke, according to background information in the article.

Paul Muntner, Ph.D., of the University of Alabama at Birmingham, and colleagues examined the Pooled Cohort risk equations in adults (age 45 to 79 years) enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study between January 2003 and October 2007, and followed up through December 2010. The researchers studied participants for whom atherosclerotic CVD risk may trigger a discussion of statin initiation (patients without clinical atherosclerotic CVD or diabetes, low-density lipoprotein cholesterol level between 70 and 189 mg/dL, and not taking statins; n = 10,997). Additional analyses, limited to Medicare beneficiaries (n = 3,333), added atherosclerotic CVD events identified in Medicare claims data.

Among the study population (n=10,997) for whom statin treatment should be considered based on atherosclerotic CVD risk there were 338 events (192 CHD events, 146 strokes). The researchers found that the observed and predicted 5-year atherosclerotic CVD incidence rates were similar.

There were 234 atherosclerotic CVD events (120 CHD events, 114 strokes) among the subset of Medicare beneficiaries and the observed and predicted 5-year atherosclerotic CVD incidence rates were also similar for the various risk categories in this population.

“These findings support the validity of the Pooled Cohort risk equations to inform clinical management decisions,” the authors write.  “Because the Pooled Cohort risk equations were designed to estimate 10-year atherosclerotic cardiovascular disease risk, studies are needed to ensure its accurate calibration over a longer duration.”

(doi:10.1001/jama.2014.2630 Available pre-embargo to the media at https://media.jamanetwork.com)

 Editor’s Note: This research project is supported by a cooperative agreement from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. Additional support was provided by grants from the National Heart, Lung, and Blood Institute. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

 # # #